University of Tennessee, Knoxville

TRACE: Tennessee Research and Creative
Exchange
Doctoral Dissertations

Graduate School

12-2014

Calcium and Leucine Modulation of Airway Inflammation
Patricia Louise Brown
University of Tennessee - Knoxville, pbrown9@vols.utk.edu

Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss
Part of the Molecular, Genetic, and Biochemical Nutrition Commons

Recommended Citation
Brown, Patricia Louise, "Calcium and Leucine Modulation of Airway Inflammation. " PhD diss., University
of Tennessee, 2014.
https://trace.tennessee.edu/utk_graddiss/3188

This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee
Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized
administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact
trace@utk.edu.

To the Graduate Council:
I am submitting herewith a dissertation written by Patricia Louise Brown entitled "Calcium and
Leucine Modulation of Airway Inflammation." I have examined the final electronic copy of this
dissertation for form and content and recommend that it be accepted in partial fulfillment of the
requirements for the degree of Doctor of Philosophy, with a major in Nutritional Sciences.
Michael B. Zemel, Major Professor
We have read this dissertation and recommend its acceptance:
Jay Whelan, Dallas Donohoe, Joseph Bartges
Accepted for the Council:
Carolyn R. Hodges
Vice Provost and Dean of the Graduate School
(Original signatures are on file with official student records.)

Calcium and Leucine Modulation of Airway
Inflammation

A Dissertation Presented for the
Doctor of Philosophy
Degree
The University of Tennessee, Knoxville

Patricia Louise Brown
December 2014

Copyright  2014 by Patricia Louise Brown
All Rights Reserved

ii

Acknowledgements
I would like to express my deepest gratitude to my major professor, mentor and
friend Dr. Michael Zemel for his support and guidance during my tenure in graduate
school at the University of Tennessee. I would like to thank Drs. Michael Zemel, Jay
Whelan, Dallas Donohoe, and Joseph Bartges for serving on my dissertation committee
and providing me with the guidance and knowledge to become an independent scientist.
I would like to express my appreciation to the Nutrition Department for providing me
with the education and support to achieve this important goal.
I would like to give special thanks to Dr. John Biggerstaff for encouraging me to
continue scientific research, recognizing my ability, and pushing me to pursue my
graduate degree. Without his mentorship, I would not be where I am today.
My deepest appreciation and love to my fiancé Dr. Benjamin Curry, without
whom I could not have made it through the trials and tribulations of graduate school. I
could not have made it here with anyone else beside of me. I love you always.
I would like to thank my parents, David E. and Judith Brown, for all of the love
and support they have given me throughout my entire life. I would also like to thank my
siblings, especially my beautiful sisters, for the long pep talks and always believing in
me. I give my deepest appreciation to the parents of my fiancé, Ken and Cindy Curry for
providing me with the opportunity to go to graduate school in a time when I did not have
the means. Finally, I would like to thank God for placing the obstacles and opportunities
in my life that led me to find my strength and know that through him anything is possible.

iii

Abstract
Over the past several decades the prevalence of obesity and asthma have
increased in a parallel fashion. Recent studies reported a positive relationship between the
two disorders that may in fact be causal. Although the link between obesity and asthma
has become widely recognized, the underlying pathophysiological connection is not
elucidated. Increased markers of inflammatory and oxidative stress are present in obesity
and asthma suggesting the link is immunological. The systemic inflammation observed in
obesity may potentially initiate adverse affects in the airways. Previous studies have
shown that consumption of dairy foods (rich in calcium and leucine) suppress 1,25dihydroxycholecalciferol (calcitriol) resulting in decreased inflammatory stress
associated with excess adiposity. Additionally, adipocyte leucine treatment was reported
to decrease pro-inflammatory TNFα and increase anti-inflammatory adiponectin
cytokines, which have been implicated in asthmatic disease. Consequently, we sought to
determine if correcting the imbalance of adipocyte inflammatory cytokine secretion via
calcium and leucine treatment would have a functional effect on airway inflammation.
We demonstrated that conditioned medium collected adipocytes (ACM) treated with
leucine for 48hrs significantly reduced monocyte-airway smooth muscle adhesion, lung
endothelial cell ICAM-1 adhesion molecule expression, and polymorphonuclear (PMN)
cell CD11b expression in vitro compared to control, while calcitriol exerted the opposite
effects. Furthermore, these findings were extended to an established murine model of
asthma. Female BALB/c mice were sensitized and challenged with chicken egg albumin
(OVA) to induce airway inflammation. Animals were fed a high fat diet with no
supplementation, high calcium (1.2%), leucine (200% normal levels), or a diet with a
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combination of calcium (1.2%) and leucine (200% normal levels). We found that the
combined high calcium and leucine supplemented high fat diet animals had significantly
less eosinophils in collected bronchoalveolar lavage fluid (BALF) compared to control
diet mice. These data suggest that calcium and leucine may have potential therapeutic
affects on obesity associated airway inflammation.
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Part One
Introduction
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Introduction
Asthma prevalence has increased in industrialized nations over the past several
decades (1). The increase in asthma diagnosis has been observed in all ages, genders, and
racial groups (1). Over 300 million people suffer from asthma globally with over 25
million people living with asthma in the United States alone (2-5). The obesity epidemic
and asthma have grown in a parallel fashion and there is an increasing body of evidence
to suggest a positive relationship between the two disorders (6,7). Prospective studies
have shown that increasing BMI correlates with an increased risk of asthma development
while weight loss improves the course of the illness (8,9). Obesity is acknowledged as a
predisposing factor for asthma development. However, the underlying pathophysiological
connection remains elusive. As both asthma and obesity share many of the same
inflammatory cytokines and oxidative stress markers a likely connection may be
immunological (10-12). The chronic low-grade systemic inflammation and oxidative
stress may work synergistically to adversely modify the airways. The balance of
inflammatory and anti-inflammatory cytokines secreted by adipose tissue is altered by
oxidative stress (13). The increase in reactive oxygen species (ROS) suppresses adipose
tissue expression of adiponectin and increases expression of inflammatory factors,
including TNFα, while suppression of ROS exerts the opposite effect (13). Mitochondrial
uncoupling status and cytosolic Ca2+ signaling, both of which are regulated by calcitriol
(vitamin D3) modulate adipocyte ROS production (14-16). Calcitriol suppresses the
expression of adipocyte uncoupling protein 2 (UCP2), resulting in greater mitochondrial
membrane potential, and stimulation of cytosolic Ca2+ signaling, both of which lead to
increased ROS production (14-17). We have recently shown physiological concentrations
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of calcitriol (100pm-10nM) similar to levels observed in calcium deficiency stimulated
the expression and secretion of inflammatory cytokines, including TNFα, while inhibiting
adiponectin expression and secretion (14-17). These concentrations of calcitriol stimulate
ROS production in both murine and human adipocytes (14-17). Further, we have shown
calcitriol to exert comparable effects in macrophages and to stimulate macrophageadipocyte cross talk and inflammatory response in co-culture (17).
Consequently, we evaluated the ability of dietary calcium-induced suppression of
circulating calcitriol to attenuate oxidative and inflammatory stress and found significant,
substantial suppression of both adipose tissue and systemic oxidative and inflammatory
stress in a mouse model (14, 18). These findings were extended to a randomized, blinded
cross over clinical trial in overweight and obese subjects where it was found that
suppressing circulating calcitriol with a calcium-rich diet suppresses systemic oxidative
stress by ~20%, reducing TNF-α and increased adiponectin by 20% (p<0.002)(18).
Recent studies support a role for leucine in attenuating oxidative and inflammatory stress
has been supported (19,20). We have found 0.5 mM leucine (comparable to levels
achieved following a leucine-rich meal) to stimulate mitochondrial biogenesis in both
adipocytes and muscle cells, with an associated increase in oxygen consumption and fatty
acid oxidation in both cell types (20). This increase in energy utilization reduces the
oxidative and inflammatory stress that otherwise results from nutrient overload and
obesity.
The purpose of this work was to determine if leucine and calcium treatment have
a functional effect on the obesity associated airway inflammatory process using both in
vitro and in vivo models.
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2.1 Asthma
2.1.1 Overview
Asthma is an inflammatory disease of the airways affecting more than 300 million
people worldwide1 with over 25 million living in the United States in 20102-4. Urbanized
nations such as the US have reported increases in asthma prevalence among all racial
groups, ages, and genders over the past thirty years 5. As the leading childhood chronic
illness, asthma affects more than ten million American adolescents and children6. By the
year 2025, the number of childhood asthmatics in the US is expected to exceed 100
million7. Although modern treatment has helped lower mortality8,over 250,000 people
die annually from asthma related symptoms9. Asthma can affect people of any age. The
term ‘phenotype’ has been initially used to describe the heterogeneity in asthmatic
manifestations10. Asthmatic phenotypes/endotypes are characterized based on criteria
such as: presence of allergy, severity, pathology (eosinophilic, noneosinophilic) and age
of onset among other factors11-17. Endotype is a relatively new concept in asthma
classification18. The term was introduced to specially describe subphenotypes in asthma
that include distinctive or unique pathological or functional mechanism such as aspirinsensitive asthma, early onset allergic asthma, neutrophilic and obesity- related, Th2
associated, severe late onset eosinophilic, non Th2 associated and bronchopulmonary
mycosis13. Collection of adequate laboratory and clinical data on each asthmatic patient is
needed before an appropriate definition of specific phenotypes can be determined18.
Therefore, characterizations of all the distinct asthmatic phenotypes and pathologies have
yet to be fully elucidated.
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2.1.2 Disease Description
Many different cell types participate in the pathology of asthma mast cells and
eosinophils are critical in the airway inflammatory process while leukotrienes, cytokines,
histamine mediators and T lymphocytes are also involved10. Pathologies such as airway
inflammation as well as airway hyper-responsiveness (AHR) associated with reversible
airflow obstruction are traditional attributes of asthmatic disease19. Classic clinical
symptoms of asthma patients are recurrent episodes of wheeze, shortness of breath, and
coughing due to abnormalities in the airways2. Several other symptoms such as bronchial
hyper-responsiveness and airway obstruction typically associated with asthma are also
pathologically linked to other disorders such as obstructive sleep apnea, obesity,
stressors, reflux or atopy20. Asthma attacks (acute exacerbations) pose the biggest threat
to the asthmatic patient. Exacerbations are episodes of airway obstruction (chest
tightness, shortness of breath, coughing, and wheezing) that may result in loss of lung
function or death21. Asthmatics experience these recurrent episodes of airflow
obstruction, airway hyper-responsiveness and inflammation in response to irritants,
allergens, cold air, or exercise exposure22. Symptom control is crucial to improving the
severity and frequency of life threatening acute exacerbations. Defining the underlying
pathologies of distinct asthmatic phenotypes is the key to providing proper individualized
treatments22.
2.1.3 Pathology
The underlying pathophysiological mechanism of asthmatic disease involves a
dysfunctional multisystem response including airway epithelium, airway smooth muscle,
and circulatory system22. Histological changes involve epithelial damage, thickening of
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the basement membrane, mucus production and airway smooth muscle (ASM)
thickening.22,23 The frontline defense for healthy airways against allergens or stimuli in
the environment is the airway epithelium24. Asthmatics however, suffer from incomplete
formation of tight junctions in the airway epithelium that are defective in preventing
allergen infiltration into the airway tissue24. Damage to epithelium and composing
epithelial cells is a result of chronic airway inflammation20. This airway inflammation is a
result of leukocyte infiltration and subsequent cytokine secretion. Eosinophils are one of
the first major cell types recruited to sites eliciting an inflammatory response25-27. Asthma
development and progression are affected by eosinophil secretion of lipid mediators,
reactive oxygen species (ROS), cytokines, and toxic granule proteins28. Eosinophils play
an active role in asthmatic airway remodeling through several mechanisms. Interactions
with epithelial and mesenchymal cells, release of cationic proteins, cytokines, and
eosinophil-derived TGF-β are all contributors to eosinophil influenced airway
remodeling29-31. Necrotic airway epithelial cell cellular debris, mucin produced by goblet
cells, eosinophils, lymphocytes, neutrophils, and plasma protein exudate make up the
composition of mucous32-34. Over the past several years there has been an emerging
interest in asthma airway remodeling mechanisms35. Remodeling and inflammatory
processes work interdependently to induce structural changes in the asthmatic airway36.
Airway remodeling has been suggested to be a consequence of injured airway epithelial
cells that work as an incessant stimulus for the process35. Reactive oxygen species (ROS)
generated from resident inflammatory cells in the lung are key contributors to asthmatic
pathophysiology37. Diminished β-adrenergic receptor response, airway
hyperresponsiveness, elevated vascular permeability, mucus hypersecretion, secretion of
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neuropeptides, and release of chemoattractants can all result from the production of
reactive oxygen species 37-42. Numerous enzymatic and non-enzymatic antioxidants work
to protect the lungs and blood from ROS generated from mitochondria as a consequence
of regular cellular metabolism43. Obesity increases systemic oxidative stress which alters
adipokine secretion by decreasing anti-inflammatory adiponectin while increasing
inflammatory cytokine secretion44-46. Oxidants induce the inflammatory process while
antioxidants reduce oxidative stress and ameliorate adverse adipokine secretion44-46. It
remains unclear which of these aspects of pathogenesis is the initial stimulus for disease
manifestation. Traditionally, the classic asthmatic phenotype presents high IgE levels
accompanying eosinophilia in the airways20.
2.1.4 Airway Inflammation
Asthmatics suffer from chronic airway inflammation20. Inflammatory cells, such
as leukocytes, are responsible for secretion of potent chemical mediators that initiate
inflammation in the airways20. Classically, T helper type 2 (Th2) lymphocytes were
thought to be solely responsible for asthma initation20. First, antigen presenting cells such
as dendritic cells (DCs) would take up allergens and present them to naïve T helper cell
lymphocytes20. Allergens such as pollens, house dust mites, animal dander, fungi are
common inhaled stimulants that can be responsible for asthma sensitization20. As a
consequence of sensitization allergen specific Th2 cell production is initiated20.
Proliferation of Th2 cells stimulated by inhaled allergens increase production and release
of cytokines such as interleukin (IL)-4, IL-5, and IL-13, which contributes to asthma
development20. Modern characterization has incorporated Th9 and Th17 lymphocytes as
well in disease modulation20. It has been reported that airway inflammation can be
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induced by Th17 produced IL-22, IL-17A, and IL-17F20. Additionally, IL-17A enhances
the contractility of airway smooth muscle cells20.
Histological changes involve epithelial damage, basement membrane thickening, mucus
production and airway smooth muscle (ASM) thickening22,23. Although it is not clear
which of these factors is the most important, airway smooth muscle is an essential
element of acute airway narrowing23. The increased smooth muscle mass in different
individuals may be caused by hypertrophy and/or hyperplasia23. However, since
mammalian cells must undergo cell enlargement prior to mitosis, cell growth and
increased contractile protein expression is common to both47. Multiple signaling
pathways and growth factors are involved in regulating ASM proliferation. These include
the phosphaditylinositol 3-kinase (PI3K) pathway, the extracellular single-regulated
kinase (ERK) pathway and peptides such as platelet-derived growth factor (PDGF) and
epidermal growth factor (EGF)23.
Airway inflammation by leukocyte infiltration into airways is one of the staple
characteristics of asthmatic disease26. Polymorphonuclear cells (PMNs) leukocytes
include neutrophils, eosinophils, and basophils30. PMN subtypes have diverse roles in
immunological responses. Eosinophils, neutrophils, and mononuclear leukocytes such as
monocytes have been implicated in airway diseases27. The β2-integrin CD11b is
expressed continuously on multiple leukocyte sub populations including eosinophils,
neutrophils, and monocytes27. After stimulation with a cytokine or other mediator of
stress, leukocytes are activated and increase levels of CD11b integrin expression on the
cell surface27. This increased expression is needed for proper guidance and attachment to
resident cell types at the site of inflammation27. Upon reaching the site of inflammation
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via chemotactic guidance, eosinophils, neutrophils, and monocytes begin rolling on P and
E selectins expressed on endothelial cells27. Before infiltration is initiated the leukocyte
anchors via adhesion molecules27.
Intracellular adhesion molecule (ICAM-1) is present on vascular and pulmonary
endothelial cells as well as smooth muscle cells48. Upon injury or stimulation from stress
the expression of ICAM-1 surpasses normal levels and awaits arrival and attachment of
leukocytes48. Adhesion molecules such as ICAM-1 anchors the leukocyte and guides
infiltration into tissue48. Once leukocytes are present in the tissue, cytokine and
chemokine secretion is amplified48. The newly present mediators of inflammation recruits
more leukocytes and initiates remodeling as a consequence of ongoing inflammation48.
2.1.5 Cytokines in Atopic Asthma
The staple cytokines in classical asthma are encoded on chromosome 5q31 in the
IL-4 gene cluster50. Cytokines encoded on the gene cluster such as IL-4, IL-5, IL-13, IL-9
as well as granulocyte colony stimulating factor (GM-CSF) contribute to asthma is
different ways50. IL-4 is a Th2-cell-associated cytokine that promotes increased
expression of adhesion molecules, B-cell isotype switching, facilitates goblet cell
metaplasia, and airway hyperresponsiveness (AHR) and stimulates eotaxin secretion20,51.
2.1.6 Asthma Disparities
Although the prevalence of asthma has grown in urbanized nations in the past
several decades among all populations52, the largest percentage increase is observed in
children3. Traditionally thought of as an allergic disease it seems fitting that children with
allergies are more likely to develop asthma53,54. However, recent findings have reported
non-allergy related asthma in a large population of childhood patients53-55. These types of
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inhaled allergen sensitizations are thought to be the reason most asthma cases start in
childhood20.
Although more obvious in obese women compared to obese men56, there is an
increasing body of evidence for an association between asthma and obesity57-59. Several
cross-sectional studies have found obesity to be a predisposing factor in both children and
adults for asthma onset60. The underlying mechanism connecting obesity and asthma is a
controversial research topic. One theory proposes the increase in inflammatory and
oxidative stress observed in obesity to synergistically harm the airways61. Increased proinflammatory cytokine production from excess adipose tissue observed in obesity has
been associated with asthma61. It has also been suggested that the adipokine-asthma
association is age and sex dependent as the link is more pronounced in premenopausal
women, prepubertal boys, and peripubertal girls62,63. Perhaps there is a hormone ratio
guiding the T-cell responses in addition to excess adiposity resulting in distinguished
phenotypes64. Increased estrogen levels as experienced in phases of sexual maturity and
increased adiposity greatly influence immunological responses and may amplify obesity
related pro-inflammatory cytokine secretion64. A combination of symptoms, the degree of
bronchial obstruction, dose of inhaled corticosteroids needed for asthma control, intensity
of treatment, and inflammatory markers are criteria used to define severe asthma58.
Frequent exacerbations in severe asthma are associated with comorbidities such as
obesity, gastroesophageal reflux, obstructive sleep apnea syndrome (OSAS), and
psychological dysfunction65.
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2.1.7 Current Asthma Therapies
Albeit pathological descriptions of asthmatic disease give insight into the
established mechanistic aspects of the disease, they are not appropriate for clinical
purposes66. More practical in primary care setting breathlessness, coughing, wheezing,
and tightening of the chest define the disease, which fluctuates over time in intensity,
frequency and occurrence66. Often it is the alleviation of these symptoms that are used to
measure treatment response67.
There are several medications available to control asthma: inhaled
glucocorticosteroids, leukotriene modifiers, long-acting inhaled β2-agonists (LABA)s in
combination with glucocorticosteriods, systemic glucocorticosteroids, theophylline,
cromones, and anti-IgE. Reliever medications which include rapid acting inhaled β2agonists, systemic glucocorticosteroids, anti-cholinergics, theophylline, and short-acting
oral β2-agonists67. Most commonly, asthma is treated by inhaled corticosteroids (ICS) as
well as bronchodilators to improve quality of life and alleviate the frequency of
symptoms67. There are subsets of asthmatics that do not respond well to standardized
treatments67. Particularly, asthmatics that are also defined as obese seem to have a
treatment refractory phenotype67. A decreased response to inhaled corticosteroids used in
asthma management has been observed in overweight or obese children67. Severe
asthmatics who are of normal weight are significantly more likely to exhibit optimal
asthma control compared to overweight subjects68. Further, the optimal control state was
completely missing in severe asthmatics that were obese68. From these observations it
appears that severe asthmatic patients with good nutritional status seem to correlate with
better “controlled” pulmonary disease management68. These findings agree with previous
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studies that have shown that normal weight asthmatics have better disease control than
obese patients69. The recently observed neutrophil rich airway inflammation of obese
asthmatics may explain the treatment refractory subtype associated with excess
adiposity70,71.
2.2 Adipose Tissue
2.2.1 Adipocytes
Adipose tissue is found in two major types throughout the human body, the first
and most abundant in adults is white adipose tissue (WAT) the second is more prominent
in infants and is termed brown adipose tissue (BAT)72. White adipocytes are filled with a
single large lipid droplet and are spherical72. Adipocytes interact with the heart, liver, and
skeletal muscle as a very important component of metabolic processes73. After a meal
rich in fat, adipocytes will store TAG absorbed from the intestinal tract (chylomicrons) or
the liver (VLDL) until needed for fuel73. When additional fuel is needed for physiological
processes TAGs will by hydrolyzed to release free fatty acids by adipocyte lipases73.
Adipose tissue mass depends on the number of adipocytes and volume of each cell74. The
volume of adipocytes is determined by the removal and storage of TAGs75. Lipid
turnover or rate of TAG removal refers to the hydrolysis of TAGs (lipolysis) to remove
lipid stores from adipocytes, which is then followed by oxidation that is an irreversible
process76. Obesity (excess adipose tissue) alters rate of lipid turnover and hence decreases
the removal rate of TAGs76.
2.2.2 Obesity
Obesity is a global epidemic with extremely expensive healthcare
consequences77,78. Cancer, cardiovascular disease, type II diabetes, and asthma are among
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many consequences of obesity73. Obesity is determined by a body mass index (BMI) of ≥
30 calculated by body weight in kg divided by the height in meters squared (kg/m2)72.
Currently, in the United States over 30% of adult men and women are considered obese
and 35% are overweight (BMI >25)72. A BMI below 25 is considered normal; 25-29.9 is
overweight and ≥30 is characterized as obese72. Obesity is a consequence of consistent
intake of more calories than are expended resulting in unused calories and subsequent
excess adiposity72. The excess of dietary calories can be used in several ways. First,
excess calories can be utilized by treating them as “waste” using them as fuel for
thermogenesis (heat production) in mitochondria that are upcoupled72. Second, the excess
calories can be burned by increased expenditure such as exercise72. Third, the unused
calories can be converted to fat and stored in adipose tissue72.
Under normal conditions adipose tissue will clear the TAGs in circulation following
intake of dietary lipids79,80. By this process, adipose tissue prevents free fatty acids from
being released into circulation79,80. Obese subjects with excess visceral fat experience a
failure of adipose tissue to store the amount of excess free fatty acids and TAG79,80. The
dysfunctional adipose tissue leads to extremely high levels of systemic free fatty acids
and TAG79,80.
2.2.3 Obesity and Adipose Tissue Inflammation
Elevated levels of free fatty acids as that observed in obesity have the ability to
activate the innate immune response81. Through interaction with Toll-like receptor-4
(TLR-4) free fatty acids initiate a battery of adipose tissue inflammatory pathways79,82.
Pathways contributing to the adipose tissue inflammatory cascades include NLRP3
inflammasome-mediated83-85, endoplasmic reticulum (ER)-stress mediators86, and TLR82
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regulated pathways79. The increased systemic inflammation observed in obesity is largely
a result of these activated inflammatory pathways64. As a consequence of inflammatory
cascades in obesity adipose tissue becomes an active endocrine organ87. The term
“metaflammation”or metabolic inflammation is the result of obesity induced adipose
tissue endocrine function80,81. Chronic excessive calorie intake leads to increased lipid
filling in white adipocytes resulting in cytokine release and apoptosis73. Upon adipocyte
apoptosis there is a release of free fatty acids by breakdown of stored TAG73. Monocytes
are recruited to adipose tissue due to increases in cytokine and chemokine secretion73.
Macrophages undergo a transformation from the M2 phenotype to the inflammatory M1
phenotype associated with obesity73. These activated macrophages ingest adipocyte
debris by phagocytosis73. Activated adipose tissue M1 macrophages contribute to
increased levels of inflammatory cytokines such as TNFα73, monocyte chemoattractant
protein-1 (MCP-1)88, IL-689. This inflammatory adipose tissue increases inflammatory
and oxidative stress systemically as well as locally73. It is this inflammation that links
obesity to insulin resistance and subsequent development of diabetes mellitus,
cardiovascular disease, metabolic disorders, cancer, and airway disease73. Endoplasmic
reticulum (ER) stress along with protein kinases such as c-Jun N terminal kinase (JNK)
and IκB kinase IKK that initiate release of inflammatory cytokines from adipose tissue
are induced by excess nutrients such as free fatty acids (FFA)79. Over production of IL-1β
due to increased number of macrophages in obese adipose tissue leads to increased
airway hyperresponsiveness and proliferation as well as activation of IL-17 producing
cells both of which are fundamental features of asthma66,90.
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Obesity increases M1 activated macrophages as well CD4+ Th1 cells mast cells and
CD8+ effector cells85. Decreased in the obese state are M2 macrophages Th2 cells, T reg
cells, and eosinophils.
2.3 Adipokines
2.3.1 Cytokines in Adipose Tissue
Adipose tissue secretes adipocytokines or adipokines as well as other
inflammatory mediators that significantly contribute to the systemic inflammation in
obesity87,91. Once thought as just a tissue responsible for storing energy reserves adipose
tissue has emerged as an active endocrine organ73. Adipokines or peptide hormones
produced by adipocytes have the ability to work locally (autocrine and paracrine) or
systemically (endocrine)72. These adipokines relay information to the brain and to other
tissues in the body about the content of energy reserves in adipocytes72. The first theory
postulated about adipose tissue involvement as an endocrine organ was termed the
“adiposity negative-feedback” model72. This theory postulated that when the body weight
exceeded a particular value (set point) a protective mechanism would take into effect that
would increase energy expenditure and inhibit eating behavior to prevent further weight
gain72. The model predicted that the part of the brain responsible for metabolic and motor
activity was influenced by a signal originated in adipose tissue72. Evidence of an
adipocyte derived signaling factor that matched the postulated model came with the early
nineties discovery of the adipokine leptin72. Under normal conditions, leptin modulates
eating behavior and fuel metabolism to maintain body mass and adequate fuel reserves72.
However, any alteration in adipokine production such as that observed in obesity leads to
dysregulation and subsequent chronic metabolic related diseases72. Adipokine over or
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under production is the principal link of obesity to the low grade systemic inflammation
now considered characteristic of the disease72. The increased inflammatory cytokines
have been proposed to link obesity to co-morbidities such as cancer, diabetes mellitus,
hypertension, cardiovascular disease, and asthma73.
2.3.2 Leptin
Leptin the first identified adipokine, comes form the Greek word for “thin” and
curbs appetite by influencing the hypothalamus72,92. Discovered to be the product of the
OB (obese) gene, leptin studies were first conducted in mutant mice72,92. It was reported
that mice genetically altered to not produce leptin had an insatiable appetite; high cortisol
levels, did not reproduce, and grew abnormally to become severely obese93. However,
when exogenous leptin was injected into these mice they were shown to increase
locomotor and thermogeneic activity, lose weight, and eat less93. Leptin interacts with the
leptin receptor, which is expressed primarily in the arcuate nucleus of the hypothalamus,
the part of the brain that controls feeding behavior93. In morbidly obese individuals,
leptin is found in concentrations four to six times higher than levels in a normal weight
person93. It has been suggested that due to the positive association of increased adiposity
and leptin levels, leptin may be an important link between inflammatory effects and
obesity92,93. Leptin has been associated with obesity co-morbidities including asthma94.
Increased leptin levels promote activation of alveolar macrophages in the lungs95.
2.3.3 Adiponectin
Adiponectin was first identified and described over 20 years ago by the Scherer et
al 96 and Maeda et al97 groups 98. It was once thought to be the most abundant transcript
in adipose tissue and has structural homology to both Cp196,98-101 and TNFα98,102. Known
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to have anti-inflammatory properties, adiponectin has been reported to have an inverse
relationship with BMI103. Three forms of adiponectin, have been identified in plasma of
humans and mice. Characterized by corresponding molecular weight low molecular
weight adiponectin (LMW) weighs 67kD, middle molecular weight (MMW) 136kD, and
high molecular weight 300kD, which is thought to be the most physiologically active of
the three104-107. Produced mainly by visceral fat, Adiponectin is an adipokine insulinsensitizing hormone and is generally associated with ant-inflammatory effects108.
Adiponectin is a unique adipokine in that levels decrease with excess adiposity. It has
been shown to induce anti-inflammatory cytokines IL-10 and the IL-1 receptor
antagonist, to suppress NFκB signaling, expression of adhesion molecules, and
proliferation of vascular smooth muscle cells109-111. Reduced adiponectin has been
implicated in the pathogenesis of a variety of metabolic diseases such as insulin
resistance and coronary vascular disease112,113. Therefore, a role in the pathogenesis of
asthma is also very likely since human ASM cells express adiponectin receptors (Adipo
R1 and R2)114. Although an epidemiological association between adiponectin and asthma
has not yet been demonstrated61 reports from recent studies suggest a relationship
between asthma and adiponectin levels115. Shore et al found that exogenous adiponectin
administration was sufficient to induce a 60% increase in serum adiponectin in a mouse
model of asthma resulting in significant suppression of the OVA-induced inflammatory
response and bronchial hyperreactivity116. In addition, adiponectin deficient mice exhibit
a pulmonary vascular phenotype characterized by upregulation of E-selectin and
increased perivascular inflammation117. This phenotype was even more apparent in older
mice suggesting that prolonged adiponectin deficiency as seen in obesity may lead to a
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progressive inflammatory pulmonary vascular phenotype117. Similarly, adiponectin
knockout mice (APN-/-) exhibit severe pulmonary arterial muscularization and
exaggerated allergic airway inflammation in response to chronic OVA challenge
compared to wild-type mice118. Further, low serum levels of adiponectin are associated
with increased asthma risk119 and deficient levels are observed during asthma
exacerbations in both mouse116 and human94 models. High serum levels of adiponectin
protect against asthma63 although this relationship is more pronounced in women than in
men115.
2.3.4 Tumor necrosis factor alpha (TNFα)
One of the first reports linking the metabolic abnormalities of obesity with
inflammation was a rodent study where diet induced obesity increased levels of the
cytokine TNFα120. Secreted from macrophages, mast cells, eosinophils, neutrophils,
smooth muscle cells, fibroblasts and epithelial cells in response to potential stimuli,
TNFα can augment mast cells activation via a positive autocrine feedback loop and
thereby induce its own production and release48. Notably, adipose tissue is also a
significant source of TNFα, with increased levels found with increased adiposity73. The
effects of TNFα are multiplex; it increases the transepithelial migration of neutrophils by
increasing the expression of adhesion molecule such as ICAM-1 and VCAM-1 which
promotes chemotaxis of eosinophils and monocytes, it has a role in T-cell activation, has
powerful growth-promoting effects on myofibroblast proliferation and induces
hyperreactivity48,49,121,122. Accordingly, TNFα blocking strategies were demonstrated to
suppress airway inflammation in a murine model of asthma123 Further, patients with
asthma have increased levels of TNFα in bronchoalveolar fluid collected from their
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airways124. Some studies have suggested a relationship between the severity of asthma
and levels of TNFα20. The difficulty in controlling and treating the phenotype of obese
asthmatics could be the result of elevated TNFα levels48,49.
2.4 Asthma and Obesity Connection
2.4.1 Oxidative Stress
In addition to inflammatory stress, obesity and asthma are also associated with an
increase in oxidative stress biomarkers in mice and humans40,125,126. This increase is most
likely due to the underlying airway inflammation with recruitment and activation of
inflammatory cells producing reactive oxygen species (ROS)127. Oxidant stress also
promotes epithelial damage and inflammation as well as airway smooth muscle
contraction and induction of airway hyperresponsiveness 128-130. Oxidative stress alters
the balance of inflammatory and anti-inflammatory cytokines secreted by adipose tissue;
increased ROS suppresses adipose tissue expression of adiponectin and increases
expression of inflammatory factors, including TNFα44, while suppression of ROS exerts
the opposite effect131. Thus the combination of both conditions may have synergistic
effects and may contribute to the severity of asthma observed in obese subject2.
2.4.2 Calcitriol and Adipocyte Derived Oxidative Stress
Adipose tissue is a significant contributor to systemic oxidative stress125. Fat
accumulation stimulates NADPH oxidase 4 (Nox 4), a key factor in cellular ROS
production44 resulting in elevated ROS with excess adiposity. Adipocyte ROS production
is modulated by mitochondrial uncoupling status and cytosolic Ca2+ signaling, both of
which are regulated by calcitriol in murine and human adipocytes 132-134. Calcitriol
suppresses the expression of adipocyte uncoupling protein 2 (UCP2), resulting in greater
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mitochondrial membrane potential, and stimulates cytosolic Ca2+ signaling, both of which
lead to increased ROS production 131,133,134. It was recently shown that physiological
concentrations of calcitriol (100pM-10nM) dose-dependently stimulate ROS production
in both murine and human adipocytes via both Nox 4- dependent and Nox 4-independent
mechanisms and concomitantly stimulate expression and secretion of inflammatory
cytokines, including TNFα, while inhibiting adiponectin expression and secretion
131,133,134

. Further, calcitriol exerts comparable effects in macrophages and stimulates

macrophage-adipocyte cross talk and inflammatory response in co-culture131.
2.5. Asthma and Obesity
2.5.1 Common Pathologies
In industrialized countries obesity and asthma are worrisome and growing public
health issues68. The overweight and obese population are not only more likely to develop
asthma but also seem to have a harder to control phenotype of asthmatic disease that is
often refractory to standard treatments60,135. Obesity is now emerging as a widely
accepted promoting factor for asthma136. Although, the link between the disorders is
becoming undeniable, the mechanistic pathology of this association remains elusive137.
Several factors may explain the link between obesity and asthma. The mechanical load of
excess adiposity may lead to an overall reduced pulmonary function which includes a
reduction in the functional residual capacity and a lower tidal volume resulting in
shortened airway smooth muscle, decreased tension, and greater muscle stiffness137, 138,
possibly leading to bronchial hyperresponsiveness. However, this is unlikely to be a
primary mechanism, as increased risk is found with even modest increases in body mass
index. Obesity and asthma share common inflammatory and oxidative stress markers that
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suggests the relationship may be immunological2. One potential connection between the
two disorders lies in the low-grade systemic inflammation that characterizes obesity80.
The risk for asthma increases with increasing BMI, while weight loss can improve the
course of the illness. Camargo et al. found a positive association between asthma
incidence and body mass index in the Nurses’ Health Study II47. Over 85,000 women
were followed for 4 years in the Nurses’s Health Study II, including 1,500 who had
asthma47. The study reported that as the definition of asthma became more specific, the
positive relationship between asthma incidence and body mass index became stronger47.
Data from the Coronary Artery Risk Development in Young Adults study, however,
found only women showed a significant association between obesity and asthma139.
Although the study followed participants over 10 years, only 310 of the 4,547 people had
asthma139. Similarly, Canada’s Nation Population Health survey also found the selfreported asthma and body mass index to be associated only in women56. A pitfall of this
study, however, is that asthma was self-reported and not clearly defined56. Also, the
sample size of 127 women and 49 men participants with asthma was very small
compared to the over 9,000 total in the study56. A study conducted with Finnish
participants found an increased risk in asthma in adults over 30 years of age if they were
obese in their teen years140. Furthermore, the same study found that participants that were
obese in adulthood (31 years of age) as well as in their teen years (14 years of age) were
twice as likely to suffer from adult asthma compared to those that were not obese at either
point140. A study conducted by Guerra et al found an increased risk of future asthma
diagnosis in participants with a body mass index of over ≥28 kg/m2 141. However, the
study also found this association less strong in men compared to women141. A recent
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follow-up in Finnish twins found participants with a normal body mass to have
substantially lower risk of asthma development than obese participants142. A moderate
increase in risk for asthma development in obese adults was also found in the National
Health and Nutrition Examination Survey (NHANES) I Epidemiologic Follow-up Study
143

. Notable in all these prospective studies, obesity preceded asthma development60.

Children and adolescents also exhibit an association between obesity and asthma in
prospective studies144. The Children’s Health Study found that obese and overweight
boys had a significant increased risk of asthma development, but the association was not
found in girls145. However, a study in US cities found the risk of asthma was positively
associated with body mass index in female participants but not males in children 6 to 14
years of age146.
Researchers have yet to agree upon a unified definition of the disease due to the
complexity of the group of airway conditions classified under the asthma umbrella55. The
absence of a proper definition of asthma has left different definitions used in different
research projects55. Criteria for individual study definitions may be based on pulmonary
function tests, questionnaire data, or clinical symptoms depending on the researcher55. In
recent years, new asthmatic phenotypes have been reported in up to 50% of adult
asthmatics that do not have eosinophilic inflammation, are not IgE dependent, and are not
atopic147. Though immunological mechanisms may vary between the two, both nonatopic and atopic asthma are reported to have similar clinical symptoms148. New
phenotypes such as the unique obese asthmatic phenotype have emerged based upon
distinct airway inflammatory biomarkers137.
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Initial hypotheses about obesity-associated asthma did not regard airway
inflammation as a physiological link between the two disorders137,149. However, recent
studies have reported that obese asthmatics have a neutrophil dominant type of airway
inflammation70. The emerging evidence suggesting neutrophilic-based airway
inflammation in obese asthmatics is particularly pronounced in women71,150. One such
study, found that increased neutrophilic airway inflammation and obesity are
associated151. Obesity-associated phenotype is regarded as one of the most difficult to
control and treatment refractory phenotypes of asthma151. Symptoms that are left
uncontrolled result in more frequent acute exacerbations (asthma attacks) and a higher
likelihood of lung function loss and even death151. It is possible that the suggested
neutrophil predominant airway inflammation in obese asthmatics may explain the failure
of conventional therapies71,152,153.
2.5.2 Weight Loss in Obese Asthmatics
In support of the obesity and asthma connection, several studies have shown
weight loss to improve the course of asthmatic illness154-158. Bariatric surgery resulted in
significant improvements of clinical symptoms in morbidly obese asthmatics154-158.
Furthermore, studies by the Macgregor et al154 and Dhabuwala et al157 reported that
airway conditions were resolved in up to 50% of patients with asthma after receiving
weight loss surgery. Quality of life in terms of asthma severity score, hospitalization,
number of attacks, and medication use significantly improved in up to 90% of obese
asthmatics after bariatric surgery60. A study conducted in Swedish obese asthmatics
found patients surgically treated had substantial reductions in medication costs compared
to those treated with conventional methods159. Studies involving obese asthmatics and
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bariatric surgery are have shown promising results, however, study design, definitions of
asthma, objective measures, and post surgery diet variations across trials are worth
noting60. The absence of control groups in the obese asthmatic bariatric studies, lack of
definitive measures of medication use, as well as absent bronchial reactivity and
pulmonary function data have sparked some debate about interpreting results60.
Additionally, some would argue that the improvement of the composition of diet as well
as decreased energy intake after surgery might at least in part be responsible for
respiratory health improvements opposed to weight loss alone154,160.
2.5.3 Diet Interventions in Obese Asthmatics
The effects of weight loss on asthmatic symptoms have been examined in studies
using non-surgical interventions in obese asthmatics such as diet modification161. The
Stenius-Aarniala et al used a very-low-calorie diet implemented for an eight week
duration in a randomized clinical trial to induce weight loss in obese asthmatics and
observed favorable changes in forced expiratory volume (FEV1), health status, dyspnea,
forced vital capacity (FVC), number of acute exacerbations (asthma attacks), as well as
use of rescue mediation were observed in those assigned to the very-low calorie diet in
measurements taken at the end of the 8 week period and a year later161. On average those
in the experimental diet group ended the study with a 14.5% reduction in their body
weight, possibly explaining disease improvement161. A similar study reported a 14%
body weight loss in obese asthmatic fed very-low-calorie diet for 8 weeks162. Participants
in the experimental diet group were observed to have improvements in day-to-day
variation, FEV1, peak expiratory flow, ratio of forced midexpiratory flow rate to FVC,
FVC, expiratory reserve volume, resting minute ventilation, diurnal variation and
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functional residual capacity162. Albeit uncontrolled, another study utilized diet
modification in obese asthmatics by 6 or 12-week study design based on the degree of
obesity where patients were place on a 900kcal/day diet163. The average participant lost
17.4% of their pretreatment weight163. This study also introduced an exercise component
that may explain the increase in body mass loss compared to studies using only diet
interventions163. Positive changes were observed by the improvement of total lung
capacity, FVC, and FEV1, however, bronchial reactivity was unchanged163.
2.6 Dairy Food Components, Asthma, and Adipose Tissue Inflammation
2.6.1 Dairy and Asthma
Despite controversial claims suggesting that milk or dairy consumption may
trigger asthma attacks or promote mucus production, supporting scientific evidence for
these claims is scant and could be found only for subgroups of patients and is confounded
by claims regarding the source of the milk and underlying medical conditions 164. In
contrast, epidemiological studies suggest a protective role for dairy products, calcium and
Vitamin D intake in the development of allergic disease and asthma 165-168. A study
reported by Wijga et al.165 found that daily full cream milk and butter consumption at age
2 significantly lowered the subsequent incidence of asthma and wheezing at age 3 (3.4%
vs. 5.6% and 13.7% vs. 18.4%, respectively). Waser et al 168recently found an inverse
association of farm milk consumption with asthma in schoolchildren from rural and
suburban populations across Europe, and Hijazi et al.166 reported low intake of milk as a
significant risk factor for wheezing illness. Moreover, a prospective study167 examining
the association between maternal consumption of dairy products, calcium and vitamin D
during pregnancy and the later risk of wheeze and eczema in the infants found a
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decreased risk of infantile wheeze with higher maternal intake of total dairy products,
milk, cheese, calcium and Vitamin D during pregnancy. Multiple components in dairy
may be responsible for these protective effects. One study found that cis-9, trans-11conjugated linoleic acid, a naturally occurring fatty acid in milk fat, significantly
inhibited airway inflammation, airway hyperresponsiveness and mucous plugging in a
murine model of asthma, which may explain the protective effects of butter and full
cream milk169. In another study, Lee et. al 170 administered kefir powder through
intragastric feeding to a mouse model of asthma and found significant anti-inflammatory
and anti-allergic effects after treatment. Although the authors suggested that these effects
might be caused by the high microbial content of kefir, it is plausible that other
components such as calcium and leucine may also play a significant role; which supports
the premise presently in review.
2.6.2 Dietary Calcium Suppression of Calcitriol
The ability of dietary calcium-induced suppression of calcitriol (elevated in
calcium deficiency; ~70% of the obese) to attenuate oxidative and inflammatory stress
was shown by Zemel et al where a significant, substantial suppression of both adipose
tissue and systemic oxidative and inflammatory stress in a mouse model was reported
132,171

. The findings prompted the dietary interventions to be extended to clinical trials in

overweight and obese subjects where it was found that suppressing circulating calcitriol
with calcium-rich diet suppressed systemic oxidative stress by ~20%, reduced circulating
TNFα and increased adiponectin by 20% (p<0.002) in a randomized, blinded cross-over
trial design171,172. Although calcitriol has been recently reported to inhibit ASM
proliferative response to PDGF173, this effect occurs at concentrations that are 50-500
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fold higher than physiological plasma concentrations (IC50=520nM). These
concentrations may be achieved in some tissues, such as the prostate, in vitamin D replete
individuals and are relevant to autocrine signaling, but are not relevant to the endocrine
signaling role of calcitriol proposed in Zemel et. al studies among others.
The two broad categories of vital calcium function are structural and signal
transduction73. Calcium is considered to be the “universal second messenger”73. As
secondary messenger calcium is responsible for nerve conduction/neuromuscular
transmission, muscle contraction, membrane transport, hormone secretion, blood
coagulation, cell growth, cell division, cell adhesion73. Less than one percent of skeletal
calcium is available for exchange on short notice and this fraction is found in the
extracellular bone fluid surrounded by “osteocytic membrane system”73. This is also the
system involved with bone remodeling regulating bone resorption and deposition as well
as osteoclast activation73. In the plasma, calcium exists as the ionized form (Ca2+)
representing ~50% of total plasma calcium73. The second most prominent form of
calcium is protein bound composing about 45% of circulating calcium73. Approximately
five percent of plasma calcium is complexed in the form of Ca-citrate, Ca-lactate, Cabicarbonate, or Ca-phosphate73. Ionized calcium and complexed calcium are both
considered as ultrafilterable73. After kidney filtration of calcium, 98-99% is reabsorbed, a
process that is regulated in part by the parathyroid hormone73. Calcium enters cells via
parathyroid activated calcium channels and is transported across the cell by calbindins
that are up regulated by calcitriol73. The Ca2+ ATPase regulated by parathyroid hormone
and calcitriol along with the 3Na+/Ca2+ exchanger transport are responsible for calcium
extrusion72. In the gastrointestinal tract calcium is absorbed by active transport at the
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brush border by Ca-dependent-ATPase, although some transport is passive72. The
transport is regulated by calcitriol, which is elevated when calcium intake is low and
decreased once calcium intake is adequately restored72. Absorption is decreased with
complexation such as binding to oxalic acid (from dietary sources) resulting in insoluble
salt crystals73. Additionally, high-fiber foods and whole-grain foods high in phytic acid
decrease calcium absorption in a similar way73. Further, long term use of medications,
such as corticosteroids may also alter calcium absorption73. An alkai intestinal
environment decreases calcium absorption due to the necessity of acidic conditions for
calcium carbonate to dissolve73. Therefore, high protein diets that increase intestinal
acidity in turn facilitate calcium absorption73. Once calcium carbonate is dissolved in the
intestine it can then be absorbed into the blood73. A normal blood calcium level is ~ 2.22.6 mmol/L or 9-10.5 mg/dL total calcium and if levels fall below this range the
parathyroid gland is stimulated to release parathyroid hormone (PTH)73. Parathyroid
hormone increases Ca2+ uptake and stimulates 1α hydroxylase activity in the kidneys to
convert 25OH vitamin D to 1, 25-diOH vitamin D (calcitriol)73. Calcitriol then stimulates
Ca2+ uptake in the intestines as well as stimulates Ca2+ release from the bone to restore
calcium levels to a normal range73. If calcium levels increase above the normal range, the
thyroid gland is stimulated to release calcitonin, which stimulates Ca2+ deposition in the
bones and reduces uptake in the intestines as well as the kidneys, thereby reducing
plasma calcium levels73.
The label of “vitamin D” is used to describe both D3 (cholecalciferol) and D2
(ergocalciferol) forms of the micronutrient 174,175. Most terrestrial animals and living
plants can produce one or both major forms of vitamin D 174. Typically, vitamin D2 is
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major form synthesized in plants due to the interaction of the provitamin D2 ergosterol
and ultraviolet B light 176. Humans can only synthesize D3 but can metabolize both D2
and D3174. The more active form of vitamin D is vitamin D3 that is found naturally in
very few foods 177. Natural sources of vitamin D3 are mainly fatty fish such as mackerel,
sardines, and salmon177,178. The chief dietary sources of D3, outside of these natural
sources, are fortified foods such as select cereals and milk178. The average person
typically obtains only ten percent of their vitamin D from dietary sources174. For most
people, the main supply of vitamin D3 is produced from the interaction of a chemical in
the skin with UV radiation from the sun175 179. The chemical 7-dehydrocholesterol, or
provitamin D3 (found in the dermal layers of the skin), forms cholecalciferol after being
acted upon by UV radiation175,179 174. Cholecalciferol is then converted to 25hydroxycholecalciferol (25OHD , or calcidiol) by enzymatic action in the liver175,179,180.
Circulating vitamin D, whether obtained from synthesis in UV-exposed skin or from the
diet, is stored in adipose tissue or rapidly converted to 25OHD

180

. After this reaction,

the mitochondrial enzyme 1, α-hydroxylase (CYP27B1) is needed to convert 25OHD to
the primary active form of calcitriol (1α, 25-dihydroxycholecalciferol) 175,179,180. The
CYP27B1 enzyme is expressed in many tissues throughout the body including the
placenta and kidneys175,179,180. The now active calcitriol plays a critical role in calcium
homeostasis in the body 174,180.
Vitamin D is a secosteroid hormone72. As a steroid hormone vitamin D acts via a
receptor superfamily72. Once vitamin D binds to a receptor, it exposes a DNA binding
region and subsequently increases transcription of some mRNAs and decreases
transcription of others72. The vitamin D receptor is present in many tissues and helps to
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carry out multiple functions72. A steroid hormone functions by binding to its counterpart
where the now complexed steroid-receptor complex will translocate to the nucleus72. In
the nucleus, the complex will bind to a DNA regulatory site and regulate transcription of
multiple mRNAs and subsequent protein translation in the cytoplasm72. Vitamin D
increases calcium and phosphorus absorption from the gastrointestinal tract (GI),
increases calcium binding proteins such as calmodulin, increases calcium transport,
increases renal calcium reabsorption, and increase mature osteoclasts to mobilize calcium
and phosphorus from bone72. Free calcium in the cell [Ca2+] is around 100nM while free
Ca2+ in the blood is around 1.2 mM73. Calcium release from the bone is also increased
when levels of calcitriol are increased73. When calcium levels are adequate in the body
calcitonin is released, which then inhibits the release of calcium from the bone73.
2.6.3 Leucine and Oxidative Stress
Dairy protein is rich in branched chain amino acids, including leucine. Recent
data supports a role for leucine in attenuating oxidative and inflammatory stress181,182. We
have found leucine (0.5 mM, comparable to levels achieved following a leucine rich
meal) to stimulate mitochondrial biogenesis in both adipocytes and muscle cells, with an
associated increase in oxygen consumption and fatty acid oxidation in both cell types182.
This increase in energy utilization reduces the oxidative and inflammatory stress that
otherwise result from nutrients and overload and obesity. The positive effects of leucine
on mitochondrial metabolism have been shown to be mediated, at least in part, by sirtuin
1 (Sirt1), as leucine stimulates Sirt1 activity, while knockdown of Sirt1 inhibits leucinestimulation of mitochondrial biogenesis and metabolism182,183. To test the systemic
effects of leucine and calcium (in the form of dairy foods) on Sirt1, an ex vivo approach
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was utilized to examine the integrated effects of dairy diets in adipocytes and skeletal
muscles183. Serum from 20 overweight and obese subjects fed low or high dairy diets for
28 days were used to reflect the integrated systemic response to the diets and was then
added to culture medium (similar to a conditioned medium approach) to treat cultured
adipocytes and muscle cells for 48 hours183. Serum from participants fed a high, but not
low dairy diet, resulted in a 40% increase in Sirt1 expression vs. baseline serum in both
tissues (p<0.01) and a 30% increase in Sirt1 activity in adipocytes (p<0.05)183. This was
associated with increased expression of adipocyte mitochondrial NADH dehydrogenase
and UCP2 (p<0.04) and muscle UCP3, NRF1, and COX7 (p<0.03)183. Sirt1 activation of
PGC1-α not only drives an increase in mitochondrial energy metabolism, but also induces
antioxidant enzymes such as manganese superoxide dismutase184 and inhibits NF-κB
activity182,184, thereby attenuating oxidative and inflammatory stress, respectively.
Accordingly, leucine markedly inhibits the expression and secretion of inflammatory
cytokines while increasing adiponectin expression and secretion ~two-fold in cultured
adipocytes181. A published microarray study demonstrated that suppression of calcitriol
by calcium feeding and increased leucine intake each up-regulated Sirt1-dependent
signaling pathways for fat oxidation and attenuation of inflammatory response (including
NFκ-B signaling) and attenuated pathways such as MAPK and JAK-STAT signaling
associated with proliferations of cell cycle regulation185.
2.7 Leucine Molecular Mode of Action
2.7.1 Sirtuins
Sirtuins are a group of nutrient sensing proteins characterized as class III
deacylases that need NAD+ molecules for deacylation processes186,187. Originally
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characterized as a repressor of gene transcription at selected loci by acting as a chromatin
silencing component the first identified sirtuin protein silent information regulator 2
(SIR2) was discovered in yeast188. Sirtuins are energy sensing proteins that are dietsensitive, anti-aging, and are conserved187. The anti-aging properties of sirtuins defined in
yeast, fruit flies, C.elegans and were also found to be conserved in mammals189,190. Three
sirtuin proteins (Sirt1, Sirt6, and Sirt7) have been found to localize in the nucleus where
they regulate gene transcription in response to energy changes187. Only recently was Sirt2
also found in the nucleus where it is distinct in function by modulating cell cycle
control191-193. The other three sirtuins Sirt3, Sirt4 and Sirt5 are found in the mitochondria
making up the total of seven mammalian sirtuins currently identified187. Cellular
responses can be coordinated throughout the organism in times of caloric restriction due
to the specific cellular compartments in which sirtuins are located194. Sirtuins found in the
nucleus such as Sirt1, Sirt6, and Sirt7 influence gene expression by the epigenetic process
of histone deacetylation194. Additionally, it has been found that Sirt1 influences the
activities of enzymes and specific transcription factors by deacetylation187. Mitochondrial
sirtuins Sirt3, Sirt4, and Sirt5 modulate oxidative stress in their organelle of residence
and regulate activities of metabolic enzymes195. In response to caloric restriction (CR)
mitochondrial sirtuins switch cellular processes to support mitochondrial oxidative
metabolism as well as turn on genes for stress tolerance187. In humans, Sirt1 is activated
in response to caloric restriction196 by sensing increased NAD+ levels, accordingly,
expression is reduced in obesity197,198. Sirt1 functions in key metabolic tissues such as
white adipose tissue (WAT), liver, heart, and skeletal muscle187. Gluconeogenesis is
supported by Sirt1 in the liver via peroxisome proliferator-activated receptor (PPAR) γ
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co-activator 1α (PGC-1α) and forkhead box O1 (FOXO1)199. In prolonged fasting, Sirt1
facilitates the degradation of CREB-regulated transcription co-activator 2 (CRTC2)200.
Fatty acid oxidation is promoted in the liver by SIRT1 in response to fasting by the
activation of peroxisome proliferator-activated receptor α (PPARα)201. Fatty acid
synthesis in the liver is inhibited by SIRT1 targeting of sterol regulatory element binding
protein 1c (SREBP1c) for degradation202. Systemic cholesterol homeostasis is controlled
by SIRT1 via positive regulation of the liver X receptor (LXR)203. In skeletal muscle
SIRT1 acts in a similar manner with the overall effects of reducing glycolysis and
increasing fatty acid utilization204. In this tissue, AMP-activated protein kinase and
SIRT1 share positive loop of regulation187. AMPK up regulates the gene encoding the
NAD+ synthetic enzyme nicotinamide phosphoribosyltransferase (NAMPT), thereby
increasing amounts of NAD+ necessary for SIRT1 function205,206. In turn, SIRT1 works
reciprocally by deacetylating liver kinase B1 (LKB1) resulting in the phosphorylation
and activation of AMPK207. Lipid utilization in muscle and liver is driven by SIRT1
activation of PPARγ in white adipose tissue (WAT) allowing the mobilization of fat to
peripheral tissues208. Additionally, enhanced energy expenditure is increased by SIRT1
by driving white fat browning209. SIRT1 induced white fat browning is initiated through
PPARγ deacetylation facilitating the binding of PR domain containing 16 (Prdm16)209.
The anti-inflammatory adipokine adiponectin up regulates SIRT1 protein210 whereas
caspase I degrades SIRT1 after post high fat diet activation211. Sirtuins are also beneficial
to the vascular system by activating endothelial nitric oxide synthase (eNOS) resulting in
increased ischemic tolerance212. Also, SIRT1 induced PPARα activation has shown to
protect against cardiac hypertrophy213.
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2.7.2 Peroxisome Proliferator-Activated Receptors (PPARs)
Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear
receptors that regulate gene transcription72. Currently, there have been three identified
PPAR proteins PPAR-δ, PPAR-α, and PPAR-γ214. Ligand activated PPAR proteins
respond to dietary lipid changes by altering carbohydrate and fat metabolism genes72.
Fatty acid derivatives and fatty acids are common ligands for PPAR family members that
work in conjunction with the retinoid X receptor to form heterodimers72. These
heterodimers allow for the binding of the complex to regulatory regions of DNA and
change the rate of transcription of associated genes as a result72. Genes necessary for the
differentiation of fibroblasts into adipocytes, lipid storage in adipocytes, and synthesis are
regulated by the PPARγ nuclear receptor72. Adipose tissue (both brown and white) and
liver are the two types of tissues where PPARγ is predominantly expressed72. The type 2
diabetes medication thiazolidinedione drugs activate PPARγ72. The genes that turn on βoxidation of fatty acids in the liver are controlled by PPARα72. Present in the liver,
skeletal muscle, brown adipose tissue, heart, and kidney PPARα is also needed for ketone
body formation during times of fasting72. The most important PPAR in terms of potential
drug development to treat obesity is the PPARδ, which acts in the muscle and the liver72.
Dietary lipids stimulate PPARδ to induce transcription of genes necessary for β-oxidation
as well as those that act to uncouple mitochondria to increase energy dissipation72.
Animal studies using high-fat diets have shown that transgenic mice with an always
active PPARδ to be immune to excess fat accumulation72. PPARδ activation results in
thermogenesis, fat depletion, and weight loss by stimulating fatty acid breakdown in
uncoupled mitochondria72.
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2.7.3 AMP-activated protein kinase (AMPK)
Phosphorylation by AMP-activated protein kinase (AMPK) of target proteins
results in increased substrate oxidation for energy production73. Fatty acid synthesis is
inhibited and fatty acid oxidation is activated as downstream consequences of AMPK
phosphorylation73. Primarily, these AMPK induced responses occur in the muscle and
liver and become necessary in times of nutritional deprivation73.
2.7.4 Effects on Obesity Related Oxidative Stress
We have previously reported that calcitriol increases inflammatory and oxidative
stress in murine adipocytes and muscle cells in an in vivo model while dietary calcium
suppressed calcitriol and alleviated the adverse response171,215,216. Investigations into high
calcium foods such as dairy revealed a significantly superior effect compared to calcium
alone217. Retrospective analysis of serum samples from previous clinical trials also
suggested a protective response from dairy food consumption in obese humans217.
Observations from these studies were used to design a randomized double blind study
where dairy-based smoothies significantly increased anti-inflammatory adiponectin while
decreasing IL-6, monocyte chemoattractant protein 1, C-reactive protein, and TNFα
inflammatory markers and 8-isoprostane F2α and malondialdehyde oxidative markers in
otherwise healthy overweight and obese subjects172.
2.8 BALB/cAnNHsd Mice
2.8.1 Overview
Acquired from Harlan Laboratories, the albino stock was originally obtained by
H. Bragg in 1913 and therefore called “Bragg albino” or BALB218. In 1923, MacDowell,
in Cold Spring Harbor, NY, USA, inbred the mice. In 1932, at F26 to Snell, who added
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the ‘c’ for albino218. The BALB/cAnNHsd line was derived from a breeding nucleus
obtained from the National Institutes of Health, Bethesda218. The mouse line was
generated to be susceptible to an allergy induced Th2 lymphocyte response218,219.
Susceptibility of BALB/c mice to allergic inflammation induction led to their
incorporation as models in asthma studies218,219. In a comparison study of 7 different
strains (BALB/c, BP/2, A/J, C57Bl/6, DBA/2, CBA and AKR) of mice, it was found that
mice with a Th2 bias, particularly BALB/c mice, were best for human phenotypical
characteristics of asthma219. The BALB/c mice strain is an established and well-studied
model for asthma, however information on their ability to serve as an appropriate model
for obesity is not as pronounced.
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Part Three
Specific Aims
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Our objectives are to determine the effects of calcium, calcitriol and leucine on
airway smooth muscle cell and endothelial cell function and inflammation using in vitro
approaches in human cells and in vivo studies in a mouse model of asthma. The two
dietary components under investigation, calcium and leucine, are most abundant in dairy
foods. Accordingly, results of this study may provide a unique opportunity to use dairy
products as functional foods to uncouple the relationship between obesity and asthma and
to be utilized as part of a nutritional paradigm for prevention of airway inflammatory
disease.
Specific Objective 1. Determine the in vitro effects of calcitriol and leucine
treatment of murine adipocytes on human bronchial airway smooth muscle cells
(BSMC) and lung microvascular endothelial cell (HMVEC-L) inflammation and
function.
To address this objective, BSMC and HMVEC-L were initially be cultured alone
and treated with calcitriol (10 nM), L- Leucine (0.5 mM), and Nitrendipine (30 nM) for
48 hours to assess direct effects of treatments on these cell types. Next, the indirect
effects of above treatments on each cell-type were examined in co-culture with murine
adipocytes to assess the effects of the altered adipose tissue cytokine expression in
response to the treatments on BSMC and HMVEC-L function. At the end of the
incubation cells and culture medium were collected for analysis. For both cell-types
(BSMC and HMVEC-L), outcome measures for the inflammatory response include
intracellular adhesion molecule (ICAM-1) and vascular cellular adhesion molecule
(VCAM-1) as well as their cell surface markers via flow cytometry in response to the
treatments in BSMCs and HMVEC-Ls. Further, we assessed the direct and indirect
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(measured by using conditioned media of treated adipocytes) effects of above treatments
on the adherence and of fluorescently labeled leukocytes to treated BSMCs and HMVECLs under physiological flow conditions using fluorescence microscopy.
Specific Objective 2. Determine the in vivo effects of dietary calcium and leucine on
mouse airway smooth muscle function, inflammation and airway hyper-reactivity.
Specific objective 2 extended these findings to an in vivo system by assessing the
effects of dietary calcium and leucine in an established mouse model of asthma. Effects
of the diets on airway inflammation (via bronchial alveolar lavage) were analyzed. Since
timing of the treatment relative to the onset of airway inflammation (intervention start
before sensitization vs. after sensitization) may influence the outcome, this study was
conducted in separate groups of animals either prior to or following sensitization to
differentiate between preventive and therapeutic effects of the diets.
Mouse model of asthma: Female mice were utilized, as asthma is more prevalent and
severe in women than in men, and female mice were recently reported to exhibit more
severe allergic airway inflammation than males in response to ovalbumin challenge or
house dust mite exposure (1). 6 weeks old female BALB/cJ mice, purchased from The
Jackson Laboratory (Bar Harbor, Me), were sensitized to ovalbumin to induce chronic
allergic airway inflammation as described (2) with minor modifications. Intraperitoneal
(i.p.) injections of 50 µg of Chicken egg albumin (ovalbumin [OVA]; Grade V, SigmaAldrich, St. Louis, MO) diluted in 0.1 ml of PBS was given on day 0, 4 and 7. Starting on
day 12, animals were challenged by aerosol challenge by nebulizer delivery of 2.5%
OVA diluted in PBS 3 times a week for 6 weeks. Mice assigned to nonsensitized group
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received i.p injections and aerosol challenges of PBS only. Mice were euthanized 24
hours after last aerosol challenge.
Treatment groups: Animals were randomly divided into 5 different treatment groups:
• Non-sensitized control group: fed a high sucrose/high fat diet with sub-optimal
Calcium (0.4%)
• OVA-sensitized control group: fed a high sucrose/high fat diet with sub-optimal
Calcium (0.4%)
• Non-sensitized high calcium group: fed a high sucrose/high fat diet with sub-optimal
Calcium (1.2%)
• OVA-sensitized high calcium group: fed the same diet as control but supplemented
with Calcium carbonate (1.2% Ca)
• Non-sensitized Leucine group: fed the same diet as control but supplemented with
Leucine (200% normal level)
• OVA-sensitized Leucine group: fed the same diet as control but supplemented with
Leucine (200% normal level)
• Non-sensitized high calcium/Leucine group: fed the same diet as control but
supplemented with calcium (1.2%) leucine (200% normal level)
• OVA-sensitized high calcium/Leucine group: fed the same diet as control supplemented
with calcium (1.2%) and leucine (200% normal level)
Each diet group was further divided into 2 groups, one prevention group with feeding
start before sensitization initiation, and one therapeutic group with diet start 2 days before
the first OVA or PBS challenge.
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Part Four
Leucine and calcitriol adipocyte treatment:
Opposing influences on leukocyte adhesion to cell
types of the airway
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4.1 Abstract
The increase in inflammatory cytokines observed in obesity may link excess
adiposity to asthmatic airway inflammation. We have previously demonstrated that 1,25
dihydroxycholecalciferol (calcitriol) and leucine modulate adipocyte and macrophage
inflammatory cytokine production. With the knowledge that several of these cytokines
are involved in leukocyte adhesion and infiltration into lung endothelial and bronchial
smooth muscle cells of the airway in asthmatic disease, we sought to determine if
calcitriol and leucine treatment of adipocytes could alter this inflammatory process. 3T3L1 adipocytes were treated with vehicle, calcitriol, leucine or both for 48 hrs. Adipocyte
conditioned medium (CM) was collected for incubation with U937 monocytes or whole
blood leukocyte populations for activation marker and adhesion assays or used to assess
adhesion molecule mRNA and protein expression in human lung microvascular
endothelial cells (HMVEC-L) and bronchial airway smooth muscle cells (BSMC).
Compared to control, calcitriol markedly increased adhesion of human monocytes to
BSMC by ~7 fold, from 225 ± 14 to 1557 ± 489 cells adhering/µm2 (p<0.001). Leucine
CM, however, decreased monocyte adhesion to BASM by ~40% compared to control.
Similarly, ICAM-1 adhesion molecule mRNA was significantly lower in leucine CM
treated HMVEC-L cells as compared to calcitriol CM samples (p<0.05). Protein
expression of ICAM-1 increased ~40% in calcitriol CM samples compared to control CM
(p<0.05), while leucine CM samples were decreased ~48% compared to calcitriol CM
(p<0.01). CD11b adhesion integrin expression in whole blood leukocytes treated with
calcitriol CM were increased ~67% compared to control CM (p<0.01). Conversely,
leucine CM treated leukocytes expression was reduced by ~40% compared to control CM
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(p<0.01). Data from this study suggest opposing roles of leucine and calcitriol in obesity
associated airway inflammation.
4.2 Introduction
Over the past several decades the prevalence of asthma has increased dramatically
in urbanized nations such as the United States (1-3). Upwards of 300 million people
suffer from asthma worldwide with over 24 million currently living in the US (1, 3).
Accompanying asthma as a public health issue is the upsurge of global obesity incidence
(4). With the observed parallel growth of obesity and asthma cases, an increasing body of
evidence suggests a positive relationship between the two disorders (5). Obesity is now
widely recognized as a key risk factor for asthma where relative risk has been shown by
prospective studies to increase with increasing body mass index (BMI) (5, 6). In support
of this connection, several studies have reported increased prevalence, incidence,
severity, and decreased control of asthma in obese individuals (7-11). There is increasing
proof that obesity is a prompting factor for asthma, however, the mechanistic link
between obesity and asthma remains elusive (10, 12). One hypothesis to explain the
connection lies in the increased systemic inflammation observed with excess adiposity
that is now a hallmark of obesity (13, 14, 15). It has been reported that adipokines and
cytokines derived from the adipose tissue of obese asthmatics may have a synergistic
adverse effect on the airways (16). The defined roles of most of these intermediaries in
the development of asthmatic disease have not been demarcated; however, the alteration
of anti-inflammatory adiponectin (decreased in obesity) and pro-inflammatory TNFα
(increased in obesity) adipokines has been described as potential participants in the
pathogenesis of asthmatic disease (17-22).
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Airway inflammation opulent in leukocytes (eosinophils, neutrophils, monocytes) is
frequently used to characterize asthma phenotypes (23-25). The adipokine TNFα has
been implicated in asthmatic airway inflammation in both in vitro and in vivo models (2628). The effects of TNFα are multiplex; it increases the transepithelial migration of
neutrophils by increasing the expression of adhesion molecules such as intracellular
adhesion molecule 1 (ICAM-1) and vascular adhesion molecule 1 (VCAM-1), which
promotes chemotaxis of eosinophils and monocytes (26-28). Polymorphonuclear cell
(PMNs) leukocytes especially eosinophils and neutrophils are critical pathogenic
components in asthmatic disease by infiltrating the airways (29). The cytokine-induced
increase of leukocyte activation integrins and chemotactic guidance of chemokines
recruit PMNs from the blood to the site of inflammation in the airways (29). The
interaction between intracellular adhesion molecules (ICAM-1) on vascular endothelial
cells and CD11b (β2-integrin) on leukocytes secure adhesion of PMNs to endothelial cells
(29). Contrary to the pro-inflammatory contribution of TNFα to airway inflammation the
adipokine adiponectin appears to be beneficial in airway disease (30-32). Adiponectin has
been shown to induce the anti-flammatory cytokines IL-10 and the IL-1 receptor
antagonist, to suppress NF-κB signaling, and to suppress the expression of adhesion
molecules (30-32).
In addition to inflammatory stress, both obesity and asthma are also associated
with an increase in oxidative stress biomarkers in mice and humans (33-35). Oxidative
stress alters the balance of inflammatory and anti-inflammatory cytokines secreted by
adipose tissue; increased reactive oxygen species (ROS) suppresses adipose tissue
expression of adiponectin and increases expression of inflammatory factors, including
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TNFα (36), while suppression of ROS exerts the opposite effect. Adipose tissue is a
significant contributor to systemic oxidative stress. Our lab, and others has shown
adipocyte ROS production to be modulated by mitochondrial uncoupling status and
cytosolic Ca2+ signaling, both of which are regulated by calcitriol (vitamin D3) in murine
and human adipocytes (37-39). Calcitriol (unregulated in calcium deficiency and obesity)
suppresses expression of adipocyte uncoupling protein 2 (UCP2), resulting in greater
mitochondrial membrane potential, and stimulates cytosolic Ca2+ signaling, both of which
lead to increased ROS production (37-40). We have recently shown that calcitriol dosedependently stimulates ROS production in murine and human adipocytes and
concomitantly stimulates the expression and secretion of inflammatory cytokines, such as
TNFα, while inhibiting adiponectin expression and secretion (37-40). Consequently, we
evaluated the ability of dietary calcium-induced suppression of circulating calcitriol to
attenuate oxidative and inflammatory stress and found significant suppression of both
adipose tissue and systemic oxidative and inflammatory stress in a mouse model (37, 41).
These studies also began to suggest a role for the branched chain amino acid leucine in
attenuating oxidative and inflammatory stress as well (43, 44). Leucine was shown to
stimulate mitochondrial biogenesis, oxygen consumption, and fatty acid oxidation in
adipocytes and muscle cells (43, 44). The increased energy utilization due to leucine
treatment in these cell types resulted in reduced oxidative and inflammatory stress that
otherwise would result from nutrient overload and obesity (43, 44). From this previous
data we hypothesize that the alteration in adipocyte cytokine production by leucine and
calcitriol treatment will have opposing affects on airway inflammation. We used human
microvascular endothelial cells of the lung (HMVEC-L) and bronchial airway smooth
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muscle cells (BSMC) to assess adhesion molecule expression and inflammatory markers.
Leukocytes from whole blood were used to observe CD11b integrin and activation
marker expression and subsequent adhesion to either lung endothelial or bronchial airway
smooth muscle cell monolayers.
4.3 Materials and Methods
4.3.1 Adipocyte Conditioned Medium (CM) Generation
3T3-L1 preadipocytes (ATCC, Manassas, VA) were incubated at a density of
8000 cells/cm2 (10 cm2 dish) and grown in Dulbecco’s Modified Eagle’s Medium
(DMEM) (Gibco, Grand Island, NY) containing 10% Fetal Bovine Serum (FBS) (Gibco,
Grand Island, NY) and antibiotics (1% penicillin/streptomycin) at 37° C in 5% CO2 in
air. Confluent preadipocytes were induced to differentiate with a standard differentiation
medium consisting of DMEM-F10 (1:1; v/v) medium supplemented with 10% FBS, 1
µM dexamethasone, 0.5 mM isobutylmethylxanthine, and antibiotics (1%
penicillin/streptomycin). Preadipocytes were maintained in this differentiation medium
for 3 days and subsequently cultured in adipocyte medium (10% FBS, DMEM, 1%
penicillin/streptomycin). Cultures were re-fed every 2-3 days to allow 90% cells to reach
full differentiation. Before treatments, cells were incubated in low serum medium (0.2%
FBS, DMEM, 1% penicillin/streptomycin) overnight and then washed with fresh
medium, re-fed with (2% FBS, DMEM, 1% penicillin/streptomycin) medium containing
the different treatments (vehicle, 0.5 mM leucine, 10 nM calcitriol, 0.5 mM leucine and
10 nM calcitriol combination) all obtained from Sigma (St. Louis, MO) and incubated at
37 °C in 5% CO2 for 48 hr before conditioned media collection. Adipocyte conditioned
medium was used immediately or stored at -80°C until needed.
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4.3.2 Human Lung Microvascular Endothelial Cells (HMVEC-L)
HMVEC-L cells were maintained following the distributor’s protocol (Lonza,
Walkersville, MD CC-2527), in endothelial basal medium-2 (EBM-2) (Lonza,
Walkersville, MD CC-3156) supplemented with endothelial growth medium (EGM-2)
MV BulletKit from (Lonza, Walkersville, MD CC-3202) at 37°C and 5% CO2, until
achieving a 70%-90% confluence. The cells were used at passages 5-9 for assays.
4.3.3 Bronchial Airway Smooth Muscle Cells (BSMC)
BSMCs (Lonza, Walkersville, MD CC-2576) were incubated at a density of 8000
cells/cm2 (10cm2 dish) and grown in smooth muscle cell basal medium (SmBM-2) and
corresponding bullet kit smooth muscle cell growth medium (SmGM-2) (Lonza,
Walkersville, MD CC-3182) at 37°C and 5% CO2. BSMC were utilized for assays
between passages 4-6.
4.3.4 U937 Monocyte Cell Line (U937s)
U937 monocyte cells were obtained from ATCC (Manassas, VA, USA) and
suspensions were cultured in T-75 cm2 flasks with RPMI 1640 medium (Gibco, Grand
Island, NY) supplemented with 10% FBS (Gibco, Grand Island, NY) and antibiotics (1%
penicillin/streptomycin) at 37°C and 5% CO2. Cell density was maintained between 1 X
105 and 2 X 106 viable cells/mL. Fresh medium was added every 3-4 days depending on
the number of cells.
4.3.5 Adipocyte-Bronchial Airway Smooth Muscle Co-Culture
3T3-L1 mature adipocytes and BSMCs were co-cultured using transwell inserts
with a 0.4 µm porous membrane (Corning Inc., Corning, NY) to separate adipocytes and
BSMCs, as previous described with adipocyte-myocyte interactions (45). Each cell type
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was grown independently in transwell plates and following differentiation; inserts
containing adipocytes were transferred to bronchial smooth muscle cell plates. The cells
are then incubated in DMEM-medium with antibiotics containing the indicated chemical
treatments (vehicle, 0.5 mM leucine, 10 nm calcitriol, 0.5 mM leucine and 10 nM
calcitriol combination, 30 nM nitrendipine (Sigma, St. Louis, MO), 10 nM calcitriol and
30 nM Nitrendipine combination) and incubated at 37°C in 5% CO2 for 48 hr, after
which cells in the lower well are harvested for further analysis and media collected for
subsequent experiments.
4.3.6 RNA Extraction
The Ambion ToTALLY RNA isolation kit (Ambion, Inc., Austin, Tex., USA)
was used to extract total RNA from cells according to the manufacturer’s instruction. The
concentration, purity and quality of the isolated RNA were assessed by measuring the
260/280 ratio (1.8-2.0) and 260/230 ratio (close to 2.0) by using the ND-1000
Spectrophotometer (NanoDrop Technologies Inc., Del. USA).
4.3.7 Gene Expression
Expression of HMVEC-L and BSMC 18S, intracellular adhesion molecule
(ICAM-1), vascular cellular adhesion molecule (VCAM-1), and tumor necrosis alphareceptor 1 (TNFαR1) were measured via quantitative real-time PCR using an ABI 7300
Real-Time PCR system (Applied Biosystems, Branchburg, NJ) with a TaqMan core
reagent kit. All primers and probe sets were obtained from Applied Biosystems TaqMan
Assays-on-Demand and utilized accordingly to manufacturers instructions. Pooled RNA
from each cell type was serial-diluted in the range of 0.0156-50 ng and used to establish a
standard curve; total RNA for each unknown samples was also diluted in this range. RT-

67

PCR reactions were performed according to the instructions of the ABI Real-Time PCR
system and TaqMan Real Time PCR Core Kit. Expression of each gene of interest was
then normalized using the corresponding 18S quantification. Data for each gene is
presented as a ratio of 18S.
4.3.8 Laminar Flow Adhesion Assay
BSMCs were cultured as previously described until approximately 90% confluent.
Cells were then removed from the T-75 cm2 flask with trypsin (0.25%)/EDTA (0.1 µM),
and centrifuged at 200 x g for 5 min. Cells were resuspended with 3 mL of cells culture
media and counted using an improved Neubauer cell counting chamber with trypan blue
staining to assess viability. Cells were seeded onto 40 mm glass coverslips at a final
concentration of 2.5 x105 cells/mL and incubated at 37°C, 5% CO2 for 12-24 hrs until
approximately 90% confluent. Cells were washed 3 times with phosphate buffered saline
(PBS) and fluorescently labeled with Calcein Am (Invitrogen, Carlsbad, Ca)(1 µg/mL)
for 30 min. at 37° C, 5% CO2. Afterwards, the coverslips were washed 3 times with PBS
to remove excess Calcein AM.
U937 cells (monocyte line) were centrifuged at 200 x g for 5 minutes. Cells were
resuspended in 3 mL of FBS free, phenol red free medium and counted as previously
described. Viability of U937 cells was >90% for all assays. U937 cells were adjusted to a
final concentration of 1.0 x 106 cells/mL. The cells were fluorescently labeled with 1,1′Dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI)(Sigma, St. Louis,
MO) at a final concentration of 4.16 µg/mL for 20 min. at 37°C, 5% CO2. After labeling,
the cells were topped off with FBS free, phenol red free RPMI 1640 medium and
centrifuged at 200 x g for 10 minutes. The supernatant was removed and the labeled
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U937 cells were resuspended with 3mL of either (vehicle, 0.5 mM leucine, 30 nM
nitrendipine, 10 nM calcitriol or calcitriol and nitrendipine combination) adipocyteBSMC co-culture medium (1.0 x 106 cells/mL final concentration) or by the same
chemicals and concentrations diluted in RPMI 1640 medium for direct treatments.
4.3.9 U937 Monocyte-BSMC Adhesion Assay
This assay was modified from a previously described method (46). Briefly, a
coverslip containing a monolayer of Calcein AM labeled BSMCs were assembled in a
FCS2 microscopy stage mounted perfusion system (Bioptechs Inc, Butler, PA) containing
0.5 mm gaskets. FBS free, phenol red free RPMI 1640 cell culture media (Gibco, Grand
Island, NY) was perfused across the BSMC monolayer at a flow rate of 0.5 mL/min
(shear rate=132.9 s-1) for 10 min. Afterwards, the pump was stopped and the affluent
tubing was placed in a 12 x 75 mm tube containing the prepared U937 cells in adipocyteBSMC co-culture or directly supplemented media. The pump was restarted and ran for
5.5 min., which was the optimized time to allow fluid to flow through the entire system to
the effluent end. The pump was then stopped, and the effluent end of the tubing was
placed back into the original 12 x 75 mm tube, allowing for a continuous, recycled
perfusion. The pump was then restarted and ran for 1 hr. Afterwards, unbound U937 cells
were washed off for 10 min with FBS-free, phenol red-free RPMI 1640 media. For
comparative purposes, a perfusion with the control adipocyte-BSMC co-culture media
was ran every day prior to running a perfusion with a given treatment group. This
allowed for each treatment group perfusion (leucine, calcitriol, nitrendipine, or calcitriol
and nitrendipine combination) to be normalized to the control adipocyte-BSMC coculture or vehicle direct supplemented media each day.
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4.3.10 Microscopy and Image Analysis
Microscopy was performed on a Nikon Eclipse Ti-E Epi-fluorescence microscope
(Nikon Instruments Inc., Melville, NY) equipped with an automated stage and a 20 X
objective. A 3 X 3 large image scan was taken in each of 5 random fields by multichannel capture (channel 1: excitation/emission=488/517 nm, channel 2: ex/em 550/567
nm). Image analysis was performed using Nikon Elements 3.1 software (Nikon, Melville,
NY). Binary thresholding was individually applied to both cell types to exclude nonspecific staining, generating a percent area occupied by fluorescence, which has been
shown to be a direct correlation to the cell count (47). Results are presented as the ratio of
percent area occupied by fluorescence (U937: BSMC).
4.3.11 Phlebotomy
Blood draws were approved from an ethical standpoint by the Institutional
Review Board at the University of Tennessee (IRB #8961 B). Subjects interested in
donating blood were required to meet standard inclusion criteria guidelines that were out
lined in the screening form. Blood was drawn using a 19-guage butterfly needle equipped
with a vaccutainer connection and 10-30 mL of blood was collected each time into
sodium heparin vaccutainer tubes (BD Biosciences; San Jose, CA). Blood was
immediately used for all assays described below.
4.3.12 Whole Blood Leukocyte CD11b Expression by Flow Cytometry
Whole blood samples were collected and 500 µl of each sample was placed into a
2 mL eppendorf tube. Previously generated adipocyte CM (vehicle, leucine, calcitriol,
leucine and calcitriol combination) in the amount of 500 µl was added to the 2 mL tube
and incubated with the blood at 37°C, 5% CO2 for 1 or 2 hours. After incubation, the
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whole blood and adipocyte CM mixture was fixed in 2% paraformaldehyde for 10 min.
The tubes were then topped off with PBS and centrifuged at 200 X g for 5 min. Cell
pellets were resuspended in 100 µl of primary labeling mixture containing 1 µg of mouse,
anti-human CD11b monoclonal antibody (abcam, Cambridge, MA) diluted in 1 mL of
PBS. The primary antibody was incubated at 25°C for 1 hr. The cells were washed with
PBS and centrifuged as previously described. A secondary antibody conjugated to
Alexaflour 488 (1µg of goat, anti-mouse IgG ) (Jackson ImmunoResearch Laboratories,
West Grove, PA) was diluted in 1 mL of PBS and subsequently incubated with the cells
for 30 min at 25°C. Cells were washed, centrifuged and resuspended in PBS. Flow
cytometry was performed on an Accuri C6 Cytometer (Accuri, Ann Arbor, MI). Twenty
thousand events were collected and a marker gate was set on the isotypic control. The
same gate was applied to the CD11b stained samples generating a percent of cells that are
positive for CD11b expression.
4.3.13 ICAM-1 or CD54 Expression Flow Cytometry
HMVEC-Ls were cultured as previously described. Cells (1.5 x 105) were seeded
in each well of a 6 well plate and grown at 37°C, 5% CO2 for 24-48 hrs until
approximately 90% confluent. HMVEC-L cells were washed with PBS and incubated
with 2 mL of the various adipocyte CM (vehicle, leucine, calcitriol, leucine and calcitriol
combination) for 48 hrs at 37°C, 5% CO2. After incubation, the cells were washed 3
times with PBS and removed from the wells with trypsin (0.25%)/EDTA (0.1 µM). Cells
were centrifuged at 250 X g for 5 min and resuspended in 2% paraformaldehyde for 10
min fixation. The tubes were topped off with PBS and centrifuged as previously
described. Cell pellets were resuspended in 100 µl of PBS and incubated with 1 µg of
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mouse, anti-human CD54 monoclonal antibody (Beckman Coulter, Brea, CA) for 1 hr at
25°C. Cells were washed with PBS and centrifuged as previously described. Cell pellets
were resuspended in 100 µl of PBS and incubated with 1µg of goat, anti-mouse Alexa
488 (IgG1) secondary antibody (Invitrogen, Grand Island, NY) for 45 min at 25°C. Cells
were washed with PBS and centrifuged as previously described. Pellets were resuspended
in 300 µl PBS and analyzed by flow cytometry as described above.
4.3.14 Statistical Analysis
Results are shown as mean (±SEM) values. Groups were compared by a one-way
analysis of the variance of the means (One-way ANOVA). Data was tested for equal
variances (Levene’s Test) and normality before ANOVA analysis. Differences among
groups determined by Tukey’s HSD. A P value of less than 0.05 was regarded as
indicative of a significant difference.
4.4 Results
4.4.1 ICAM-1/CD54 mRNA expression in HMVEC-L
HMVEC-L cells were harvested and mRNA extracted following 48 hr. incubation
with treated adipocyte CM. ICAM-1 mRNA was normalized to 18S providing ICAM1/18S ratio that was compared among groups. Leucine CM treated endothelial cells had
significantly reduced ICAM-1 mRNA levels compared to calcitriol CM treated cells
(p<0.05). Leucine in combination with calcitriol CM significantly reduced the amount of
ICAM-1 mRNA in HMVEC-L cells compared to lung endothelial cells treated with
calcitriol alone (p<0.05) (Figure 1).
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4.4.2 ICAM-1/CD54 protein expression in HMVEC-L via Flow Cytometry
Calcitriol CM treated HMVEC-Ls had significantly higher levels of ICAM-1
protein expression compared to control CM treated cells (p<0.05). Leucine CM treated
lung endothelial cells, however, had significantly lower levels of ICAM-1 protein
expression calcitriol CM treated (p<0.01) cells. The addition of leucine to calcitriol CM
significantly reduced the levels of ICAM-1 protein expression compared to calcitriol CM
treated cells alone (p<0.05) (Figure 2).
4.4.3 Leukocyte Activation Marker CD11b Expression Using Flow Cytometry
CD11b expression in leukocytes treated with calcitriol adipocyte CM were
increased by approximately 67% compared to control adipocyte CM treated PMNC
leukocytes (p<0.01) (Figure 3). Conversely, leucine adipocyte CM treated leukocytes
were observed to have approximately a 40% reduction in CD11b expression compared to
control (p<0.01). Upon the addition of leucine to the calcitriol adipocyte CM treated
leukocytes there was a significant reduction in the protein expression of the activation
integrin CD11b protein expression (p<0.05).
4.4.4 Laminar Flow Adhesion Assay U937 Monocytes-BSMC Monolayer
Calcitriol direct treatment, without adipocyte exposure, markedly increased
adhesion of U937 monocytes to BSMC by approximately 7 fold, from 225 ± 14 to 1557 ±
489 cells adhering/µm2 (p<0.001) (Table 4-1). Notably, this effect is not mediated by
calcium signaling, as inhibition of Ca2+ influx with nitrendipine did not reverse this
effect, and in
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Figure 4-1:
1: Effects of various adipocyte CM on ICAM
ICAM-1
1 mRNA in HMVEC-L
HMVEC cells.
Values are expressed as mean ± SEM, (n=6). * Significantly different from calcitriol CM,
(p < 0.05).
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Figure 4-2:
2: Effects of various adipocyte CM on ICAM-1
1 protein expression in HMVECHMVEC
L cells. Values are expressed as mean ± SEM, (n=6). * Significant different from control
CM, (p < 0.05). **Significant
**Significantly different from calcitriol CM, (p<0.05).
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Figure 4-3: Figure 4-2:
2: Effects of various adipocyte CM on CD11b protein expression in
whole blood leukocytes. Values are expressed as mean ± SEM, (n=6). * Significant
different from control CM, (p < 0.05). **Significant
**Significantly different from calcitriol CM,
(p<0.05).
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Table 4-1: U937-BSMC Adherence (Direct Treatments)
Direct Treatment U937-BSMC Adherence

U937s/
µm2

Control

0.5 mM
Leucine

10 nM
Calcitriol

30 nM
Nitrendipine

225 ± 14

885 ± 1

1557 ± 489

1023 ± 141
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10 nM Calcitriol + 30 nM Nitrendipine
2384 ± 247

fact resulted in further stimulation of adhesion. Nitrendipine increased monocyte
adhesion to BSMCs (p<0.05). The addition of a combined calcitriol and nitrendipine
caused a significant increase in monocyte adhesion to BSMCs (p<0.01). There was also a
slight increase in U937 monocyte adhesion to BSMCs with direct leucine treatment
(p<0.05).
Adipocyte-BSMC co-culture studies demonstrate a similar effect of calcitriol on
adherence (p<0.05), but in contrast to the direct effects of the chemical treatments,
leucine treatment resulted in an approximate 50% reduction in adhesion of U937 human
monocytes to BSMCs (p<0.001). Similar to the direct effects of the chemical treatments,
nitrendipine exerted no effect, indicating the observed effects of calcitriol are not
mediated by Ca2+ signaling. The data are summarized in Figure 4 A&B (direct) and
Figure 5 (adipocyte-BSMC co-culture).
4.5 Discussion
Leucine and calcitriol adipocyte CM appear to have opposing effects on leukocyte
activation as measured by CD11b, ICAM-1 protein expression, and monocyte-BSMC
adhesion. Adhesion molecule protein expression of ICAM-1 was increased by calcitriol
CM treatment of HMVEC-Ls whilst leucine decreases this effect compared to control.
Leucine CM appears to initiate an anti-inflammatory response in leukocytes as indicated
by the reduction in the CD11b activation marker compared to control. On the contrary,
calcitriol adipocyte CM increased leukocyte activation indicated by the significant
increase in the activation marker CD11b compared to control. However, leucine does
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Figure 4-44 A: Direct Treatment U937 monocyte adherence to BSMC mo
monolayer
nolayer

79

Figure 4-44 B. U937 cells per micrometer squared area on BSMC monolayer observed
with the various direct chemical treatments. Values are expressed as mean ± SEM, (n=6).
* Significantly different from control CM, (p < 0.05).
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Figure 4-5:
5: U937 cells per micrometer
micrometer-squared
squared area adhered to BSMC monolayer treated
with adipocyte co-culture
culture conditions. Values are expressed as mean ± SEM, (n=6).
*Significantly different from control CM, (p < 0.05).
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appear to ameliorate these effects of calcitriol as shown by the decrease in leukocyte
CD11b expression when adipocyte CM contained both calcitriol and leucine versus
calcitriol alone.
From previous studies, we know that leucine treatment of adipocytes increases the
anti-inflammatory adiponectin and decreases the pro-inflammatory TNFα (37-45).
However, the exact mechanism of how leucine adipocyte CM decreases adhesion
molecule expression, leukocyte integrin expression, and subsequent adhesion is unclear.
Leucine, when applied directly to U937 monocytes and BSMCs, increased leukocyte
adhesion. While this appears counterintuitive based on our hypothesis, it is important to
emphasize that this is a direct effect of leucine (no exposure to adipocyte metabolism),
while the more physiologically relevant effect is found in the co-culture experiment
where monocytes and BSMCs were exposed to adipocyte CM. It is likely that the
differences in adipocyte cytokine production among the various treatments (control,
leucine, calcitriol) are responsible for these functional responses. The data from this study
suggest that leucine could attenuate leukocyte activation, adhesion molecule expression,
and leukocyte adhesion resulting from excess adiposity related inflammation.
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Part Five
Leucine and calcium supplemented high fat diets
and airway inflammation in a murine model of
asthma
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5.1 Abstract
The increase in inflammatory cytokines observed in obesity may link excess
adiposity to asthmatic airway inflammation. We have previously demonstrated that 1, 25
dihydroxycholecalciferol (calcitriol) and leucine modulate adipocyte and macrophage
inflammatory cytokine production. Since, several of these cytokines are also involved in
asthmatic disease, we sought to determine if high fat diets supplemented with calcium,
leucine, or both would alter airway inflammation in an established murine model of
asthma. Diet-induced obese female BALB/c mice sensitized and challenged with
ovalbumin (OVA) were fed high fat diets with no supplementation, high dose calcium
(1.2%), leucine (24g/kg; 200% normal level), or calcium (1.2%) in combination with
leucine (24g/kg; 200% normal level) over a six-week period. Mice fed a diet
supplemented with calcium and leucine exhibited a significant decrease in eosinophil
leukocytes present in lung bronchoalveolar lavage fluid (BALF) as compared to control
diet animals (p<0.05). Our data suggests that calcium and leucine may provide a
synergistic attenuation of lung leukocyte infiltration and subsequent airway inflammation
in obesity-associated asthma.
5.2 Introduction
Asthma and obesity have increased in prevalence over the past thirty years in a
parallel fashion (1-4). Epidemiological, longitudinal, and prospective studies suggest that
the positive relationship between obesity and asthma may be a casual one (5-8).
However, the mechanistic link between the two is still elusive. As asthma and obesity
share many of the same inflammatory cytokines and oxidative stress markers a likely
connection may be immunological (9-11). It is widely acknowledged that chronic low-
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grade systemic inflammation is a hallmark of obesity and this inflammation along with
oxidative stress may work synergistically to adversely modify the airways (11-19).
Oxidative stress alters the balance of inflammatory and anti-inflammatory cytokines
secreted by adipose tissue. Increased reactive oxygen species (ROS) suppresses adipose
tissue expression of adiponectin and increases expression of inflammatory factors,
including TNFα (20), while suppression of ROS exerts the opposite effect. Adipose tissue
is a significant contributor to systemic oxidative stress. Our lab and others have shown
adipocyte ROS production to be modulated by mitochondrial uncoupling status and
cytosolic Ca2+ signaling, both of which are regulated by calcitriol (1,25
dihydroxycholecalciferol) in murine and human adipocytes (21-23). Calcitriol (elevated
in calcium deficiency and obesity) suppresses expression of adipocyte uncoupling protein
2 (UCP2), resulting in greater mitochondrial membrane potential, and stimulates
cytosolic Ca2+ signaling, both of which lead to increased ROS production (21-24). We
have recently shown that calcitriol dose-dependently stimulates ROS production in
murine and human adipocytes and concomitantly stimulates the expression and secretion
of inflammatory cytokines, including TNFα, while inhibiting adiponectin expression and
secretion (21-24). Consequently, we evaluated the ability of dietary calcium-induced
suppression of circulating calcitriol to attenuate oxidative and inflammatory stress and
found significant suppression of both adipose tissue and systemic oxidative and
inflammatory stress in a mouse model (21, 25). Data from these studies also support a
role of the branched chain amino acid leucine in attenuating oxidative and inflammatory
stress (26, 27). Leucine was shown to stimulate mitochondrial biogenesis, oxygen
consumption and fatty acid oxidation in adipocytes and muscle cells (26, 27). The
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increased energy utilization due to leucine treatment in these cell types resulted in
reduced oxidative and inflammatory stress that otherwise would result from nutrient
overload and obesity (26, 27). Consequently, we postulated that dietary calcium and
leucine would exert synergistic and beneficial effects on adipocyte cytokine secretion in
diet induced obese mice leading to attenuation of airway inflammation in a murine model
of asthma.
5.3 Materials and Methods
5.3.1 Animals and Diets
Six week old female BALB/c mice (Harlan Laboratories, Indianapolis, IN) were
fed a high fat-diet (fat increased to 45% of energy) to induce obesity (Research Diets
D12451) (Table 5-1) with either no supplementation (Control Diet), calcium raised to
1.2% (High Calcium Diet), leucine 24g/kg; 200% of normal level (Leucine Diet), or the
combination of the calcium 1.2% and leucine 24g/kg (High Calcium and Leucine Diet).
Animals were divided into two phases (Table 5-2 A-D) (40 animals in each) and were
randomly assigned to one of the four diets on either two days before the first
intraperitoneal (i.p.) injection (prevention phase) or were fed Control diets before being
randomly assigned to stay on Control diet or move to a supplemented diet on Day 10
(treatment phase). Within each phase and each diet the animals were divided so that OVA
allergic airway inflammation would sensitize half of the mice and the other mice would
serve as a PBS vehicle control animals. The animals (four/cage) were housed in
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Table 5-1: Mouse Diet Composition

Control
(Control)

High
Calcium
(HC)

Diets
Leucine
200%
(Leucine)

(0.4% Ca)

(1.2% Ca)

(0.4% Ca)

High Calcium
+Leucine
200%
(HC + L)
(1.2% Ca)

Ingredient (gm)
Casein, 80 Mesh
L-Cystine
L-Leucine
Corn Starch
Maltodextrin 10
Sucrose

200
3
0
72.8
100
172.8

200
3
0
72.8
100
172.8

200
3
18
72.8
100
172.8

200
3
18
72.8
100
172.8

Cellulose, BW200
Soybean oil
Lard
Mineral Mix S10026
Calcium Carbonate
Potassium Citrate
Potassium Phosphate

50
25
177.5
10
10
6.2
13

50
25
177.5
10
30
6.2
13

50
25
177.5
10
10
6.2
13

50
25
177.5
10
30
6.2
13

10
2

10
2

10
2

Vitamin Mix V10001
10
Choline Bitartrate
2
Macronutrients (gm/kg diet)
Protein
203
Carbohydrate
355
Fat
203
Fiber
50

203
355
203
50
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203
355
203
50

203
355
203
50

Table 5-1, Continued.

Control
(Control)
(0.4% Ca)
Macronutrients (kcal/kg diet)
Protein
811
Carbohydrate
1420
Fat
1826
Total
4057
Macronutrients (kcal%)
Protein
Carbohydrate
Fat
Total
Calcium, gm
Phosphorus, gm
Potassium, gm

20
35
45
100
4.0
4.57
5.99

High
Calcium
(HC)
(1.2% Ca)

Diets
Leucine
200%
(Leucine)
(0.4% Ca)

High Ca +
Leucine 200%
(HC + L)
(1.2% Ca)

811
1420
1826
4057

811
1420
1826
4057

811
1420
1826
4057

20
35
45
100
12.0
4.57
5.99

20
35
45
100
4.0
4.57
5.99

20
35
45
100
12
4.57
5.99
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Table 5-2 A: Prevention Phase Group A (OVA)
Prevention Phase Group A (OVA)
Control
High Ca
Leucine
High Ca
Diet
Diet
Diet
+Leucine Diet
(HC + L)
(Control)
(HC)
(Leucine)
n=5
n=5
n=5
n=5
Assigned Diet
(2 days before i.p.)

Control

HC

Leucine

HC + L

i.p. Injections
(Day 0, 4, 7)

OVA

OVA

OVA

OVA

OVA

OVA

OVA

OVA

Day 48

Day 48

Day 48

Day 48

5

5

5

5

Aerosol Challenges
(Day 12–47)
Sacrifice
Sample Size

Table 5-2 B: Prevention Phase Group B (PBS)
Control
Diet
(Control)
n=5

Prevention Phase Group B (PBS)
High Ca
Leucine
High Ca
Diet
Diet
+Leucine Diet
(HC)
(Leucine)
(HC + L)
n=5
n=5
n=5

Assigned Diet
(2 days before i.p.)

Control

HC

Leucine

HC + L

i.p. Injections
(Day 0, 4, 7)

PBS

PBS

PBS

PBS

Aerosol Challenges
(Day 12-47)

PBS

PBS

PBS

PBS

Day 48

Day 48

Day 48

Day 48

5

5

5

5

Sacrifice
Sample Size
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Table 5-2 C: Treatment Phase Group C (OVA)

Control
Diet
n=5
Assigned Diet
(2 days before i.p.)
i.p. Injections
(Day 0, 4, 7)
Switch to
Experimental Diet
Aerosol Challenges
(Day 12-47)
Sacrifice
Sample Size

Treatment Phase Group C (OVA)
High Ca
Leucine
High Ca
Diet
Diet
+Leucine Diet
n=5
n=5
n=5

Control

Control

Control

Control

OVA

OVA

OVA

OVA

Control

Day 10
(HC)

Day 10
(Leucine)

Day 10
(HC+ L)

OVA

OVA

OVA

OVA

Day 48

Day 48

Day 48

Day 48

5

5

5

5

Table 5.2 D: Treatment Phase Group D (PBS)
Control
Diet
n=5
Assigned Diet
(2 days before i.p.)
i.p. Injections
(Day 0, 4, 7)
Switch to
Experimental Diet
Aerosol Challenges
(Day 12-47)
Sacrifice
Sample Size

Treatment Phase Group D (PBS)
High Ca
Leucine
High Ca
Diet
Diet
+Leucine Diet
n=5
n=5
n=5

Control

Control

Control

Control

PBS

PBS

PBS

PBS

Control

Day 10
(HC)

Day 10
(Leucine)

Day 10
(HC+ L)

PBS

PBS

PBS

PBS

Day 48

Day 48

Day 48

Day 48

5

5

5

5
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polypropylene cages at room temperature of 22°C ± 2°C and regime of 12 h light/dark
cycle. The animals had free access to water and their experimental food throughout the
study. All animals were checked daily for any signs of disease or death and moribund
animals (as defined by the facility veterinarian) were humanely euthanized. Weight was
measured to the nearest gram at the beginning of the experiment and then weekly until
the end of the study. At the end of the study (~7 weeks) all animals were humanely
euthanized by administration of sodium pentobarbital and subsequent exsanguination by
severing the vena cava. Blood was immediately collected from the vena cava supply,
allowed to clot at room temperature, and centrifuged to obtain serum. Immediately after
euthanasia, bronchoalveolar lavage (BAL) was performed and the lungs were harvested.
The left lung was fixed in 4% formalin for subsequent H&E staining and the right lung
was flash frozen in liquid nitrogen for later experiments.
This study and all animal procedures were performed under the auspices of a
University of Tennessee Institutional Animal Care and Use Committee-approved
protocol and in accordance with PHS policy and recommendation of the Guide.
5.3.2 Induction of Allergic Airway Inflammation
The sensitization protocol was started at six weeks of age (Day 0 of the study
protocol). Briefly, half the animals in both phases (prevention and treatment) (n=40
total) were sensitized with 50-µg i.p. injections of chicken egg albumin (ovalbumin
[OVA]; Grad V, Sigma-Aldrich, St. Louis, MO, USA) dissolved in 0.1 mL sterile
phosphate buffered saline (PBS) on Days 0, 4, and 7 (28). Starting on Day 12, animals
were challenged by aerosol nebulization delivery of ovalbumin. Animals were exposed to
a solution of 2.5% OVA dissolved in PBS aerosolized by delivery of compressed air to a
nebulizer for 30 min/day, 3 days/week (to allow at least a day in between each challenge)
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from Day 12 to Day 47 (29). Non-sensitized or control animals for the disease model
from both phases (n=40) were subjected to the exact same procedures on the same days
but were not exposed to OVA. Instead PBS alone served as vehicle for the i.p. injections
as well as nebulization deliveries.
5.3.3 Bronchial Alveolar Lavage Fluid (BALF) and Serum
Lungs were lavaged twice with 1 mL of cold PBS and the lavagates were pooled
and placed on ice until centrifuged at 400 x g at 4°C for 10 min. Supernatant was
collected and stored at -80°C for later experiments. Cell pellets were resuspended in
Hank’s Balanced Salt solution and an Advia 120 hematology system (Siemens
Healthcare, Tarrytown, NY) was used to assess the total number of cells and estimate
leukocyte distributions. Aliquots of cells were also centrifuged onto glass slides at 800
rpm for 10 min by an Aerospray 7120 cytocentrifuge (Wescor, Inc. Logan, UT). These
slides were air-dried, and then stained with a methanolic Wright’s stain using the
AerosprayPro 7151 (Wescor, Inc. Logan, UT). Cell differentials were determined by
counting 300 cells under 400X magnification by a certified pathologist in the veterinary
diagnostic pathology lab at the University of Tennessee Knoxville School of Veterinary
Medicine. Blood was collected from the severing of the vena cava. Serum was isolated by
allowing blood to clot at room temperature and subsequent centrifugation. These
protocols were adapted from those described by Williams et al (30).
5.3.4 Staining Lung Tissue Sections
Lung lobes were fixed in 4% formalin and paraffin embedded. These lung
sections were stained with haematoxylin and eosin following manufacturer’s
recommendation (Newcomer Supply, Middleton, WI, USA). Stained lung sections were
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then scored by degree of epithelial hyperplasia height to assess inflammation. The
University of Tennessee-Knoxville attending veterinarian determined epithelial
hyperplasia scores.
5.3.5 Epithelial Hyperplasia in the Lung (HypEpi)
Epithelial hyperplasia is characteristic of the initial stages of airway remodeling
and indicates inflammation and the onset of asthmatic disease. Epithelial hyperplasia was
pathologically assessed by a score of 0=absent of hyperplasia, 1=twice normal height,
2=three times normal height, 3=four times normal height. The higher the score indicates
the higher degree of inflammation and airway remodeling.
5.3.6 Inducible Bronchus-Associated Lymphoid Tissue (iBALT)
Inflammation in the lung facilitates the emergence of ectopic lymphoid tissue
termed inducible bronchus-associated lymphoid tissue (iBALT). This tissue can be found
throughout the lung when inflammation or infections are present (31). Here we used the
degree of iBALT present in the lungs of the study mice to assess lung inflammation.
Bronchial associated lymphoid tissue was scored as 0=normal or no inducible lymphoid
tissue present, 1= present around bronchi and larger bronchioles, 2= present around
smaller bronchioles, 3= more around smaller bronchioles, by the attending veterinarian at
the University of Tennessee Knoxville.
5.3.7 Statistical Analysis
Results are shown as mean (±SEM) values. Comparison of means between all diet
groups was performed by one-way ANOVA. Before one-way ANOVA data was tested
for equal variances (Levene’s test) and normality. Differences among means were
assessed by Tukey’s HSD. Student’s t test was used to test for weight gain differences

96

between (OVA) and (PBS) animals in both phases within diet groups. A P value of less
than 0.05 was regarded as indicative of a significant difference. Chi-squared was used to
assess categorical data (pathological degree scoring) and a value of less than 0.05 was
regarded as indicative of a significant difference.
5.4 Results
There were significantly (p<0.05) more polymorphonuclear cell leukocytes
(PMNs) including eosinophils and neutrophils present in the bronchoaveolar lavage fluid
(BALF) of the OVA animals versus the PBS animals. There was also a much higher
degree of inflammation in the lungs of OVA-sensitized and challenged animals as scored
by inducible bronchus associated lymphoid tissue as compared to PBS vehicle animals
(Table 5-3). Further, the degree of epithelial hyperplasia was increased in OVA
challenged animals as compared to PBS challenged animals (Table 5-3). There were no
significant differences in weight gain throughout the study or abdominal fat between diet
groups in OVA or PBS treated animals. However, prevention phase animals treated with
(OVA) gained significantly less weight throughout the study than (PBS) animals in all
diet groups (p<0.01) (Figure 1). The same trend was observed in the treatment phase
although the only significant difference was observed in leucine diet animals (p<0.05)
(Figure 2). Prevention phase Group A OVA treated animals fed the combined high
calcium and leucine diet had significantly fewer eosinophils present in BALF when
compared to control diets (p<0.05) (Figure 3A). However, there no significant differences
in neutrophils present in the BALF of Group A (OVA) animals between diets. Treatment
phase Group C (OVA) animals showed no significant differences in the eosinophils
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Table 5-3: Pathology Scores of Lung iBALT and HypEpi Across Study
Pathology Scores
Prevention Phase
OVA
(Group A)

Prevention Phase
PBS
(Group B)

Treatment
Phase
OVA
(Group C)

Treatment
Phase
PBS
(Group D)

Mean
iBALT
Score

1.0952

0

1.3182

0.0238

PBS animals had significantly less
iBALT compared to OVA treated
animals

Mean
HypEpi
Score

2.8333

0

1.5455

0.1905

PBS animals had significantly less
HypEpi compared to OVA treated
animals

98

Weight Gain in Grams

Prevention Phase Weight Gain (OVA) vs.
(PBS) Animals
7
6
5
4

*

*

3

*

*
Group A (OVA)

2

Group B (PBS)

1
0
Control

Leucine

Hi Calcium

Leucine +
HC
Prevention Phase Diet Groups

Figure 5-1:
1: Prevention Phase Weight Gain Group A (OVA) vs. Group B (PBS) Animals.
Values are expressed as mean ± SEM, (n=6). *Significantly different from same diet in
opposing group, (p < 0.05).
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Weight Gain in Grams

Treatment Phase Weight Gain (OVA) vs.
(PBS) Animals
8
7
6
5
4
3
2
1
0

*
Group C (OVA)
Group D (PBS)

Control

Leucine
Hi Calcium Leucine +HC
Treatment Study Diets

Figure 5-2:
2: Treatment Phase Weight Gain Group C (OVA) vs Group D (PBS). Values are
expressed as mean ± SEM, (n=5). *Significant
*Significantly different from same diet in opposing
group, (p < 0.05).

100

Figure 5-33 A: Group A (OVA) BALF Percentage of Eosinophils. Values are expressed as
mean ± SEM, (n=6). *Significant
*Significantly different from control CM, (p < 0.05).
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present in BALF between diets (Figure 3B). Neutrophils present in BALF collected from
treatment phase Group C (OVA) animals were reduced in the high calcium versus control
diet, although this difference only approached significance (p<0.07) (Figure 4). Inducible
bronchus associated lymphoid tissue (iBALT) (Figure 5) and lung epithelial hyperplasia
(HypEpi) (Figure 6) and (Figure 7) as indicators of inflammation and airway remodeling
were not significantly different across diets. However, the control diet animals had the
largest percentage (33.3%) of iBALT scores in the severe category, while 40% of the
High Calcium + Leucine diet animals were scored in the minimal to no iBALT category
and none were scored in the severe category.
Serum adiponectin levels measured in prevention phase animals were not
significantly different between diets (Figure 8). OVA treated animals (Group A) serum
adiponectin level was significantly higher (p<0.01) than PBS (Group B) animals.
5.5 Discussion
Calcium and leucine supplementation of high fat diets were found to have only a
modest influence on airway inflammation in a murine model of asthma. A more
prominent result was expected based on previous studies where a significant reduction of
inflammatory and oxidative stress was achieved in obese mice by similar interventions
(21, 25). The reduction in obesity-induced inflammation observed in these studies was at
least in part due to the increase of the anti-inflammatory adiponectin and decrease of proinflammatory TNFα secretion from adipose tissue. Studies where comparable asthma
models were utilized such as Shore et al (32) showed significant improvement of disease
symptoms with the exogenous administration of adiponectin. Medoff et al (28) further
supported the role of adiponectin in asthmatic disease and Blacquiere et al (33) was
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helpful in deciding sample size estimates for our female BALB/c model. Serum
adiponectin levels were not significantly different in this study despite our previous
studies where
ere adiponectin levels were significantly changed with dietary intervention.

Figure 5-33 B: Group C (OVA) BALF Percentage of Eosinophils. Values are expressed as
mean ± SEM, (n=5).
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Figure 5-4:Group C (OVA) BALF Percentages of Neutrophils. Values are expressed as
mean ± SEM, (n=5).
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Table 5-4: Group A (OVA) Pathology Scores iBALT
Group A (OVA) Pathology Scores iBALT
Control

Hi Ca

Leucine

Hi Ca + Leucine

Comment

Severe
(2.0)

33.33%

0%

20%

0%

Control diet animals had the largest
percentage of scores in the Severe
category

Moderate
(1.0 -1.5)

66.667%

100%

80%

60%

High calcium diet animals contained all
their scores in the Moderate category

Minimal
(0.0-0.5)

0%

0%

0%

40%

Almost half of the Hi Ca +Leucine diet
animals were scored in the minimal to
no iBALT category
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Table 5-5: Group C (OVA) Pathology Scores iBALT
Group C (OVA) Pathology Scores iBALT

Severe
(2.0)

Control

Leucine

Hi Ca

Hi Ca + Leucine

Comment

33.33%

20%

60%

16.667%

High Calcium diet animals had the
most scores in the Severe category

Moderate
(1.5)

0%

0%

0%

33.33%

The group with highest percentage of
animals with Moderate iBALT were
fed the Hi Ca + L diet

Mild
(1.0)

50%

60%

40%

50%

Almost half of all the animals in each
diet group scored in the Mild category

Minimal
(0.0-0.5)

16.6667%

20%

0%

0%

Leucine diet animals had the highest
percentage in the Minimal category
followed by Control diet animals
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Percent of Scores in each Category

Group A (OVA) Lung Epithelial
Hyperplasia
120
100
80
60

Control

40

Leucine

20

High Calcium

0

4 times
3 times
3.5 times
4.5 times
Leucine + HC
increase in increase in increase in increase in
height
height
height
height
Score of Epithelial Hyperplasia in Comparison to normal lung
epithelial height Score=0

Figure 5-5:
5: Group A (OVA) Lung Epithelial Hyperplasia (HypEpi) Pathology Scores.
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Figure 5-6: Group C (OVA) Pathology Scores HypEpi
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Figure 5-7:
7: Prevention Phase Group A (OVA) and Group B (PBS) Adiponectin levels
measured in collected serum. Values are expressed as mean ± SEM, (n=5). *Significantly
*Significant
different from animal fed same diet in opposing group, (p < 0.05).
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However, in this study it is likely that the subtle dietary interventions used to
increase endogenous adiponectin secretion may have been more pronounced in a larger
sample size and longer study duration. Serum adiponectin levels in prevention phase
OVA animals were significantly higher than PBS animals (p<0.01). The higher
adiponectin levels in Group A OVA compared to Group B PBS animals reflects the
observation that OVA animals also weighed significantly less than PBS animals.
Treatment phase animals did not yield the same results as prevention phase animals,
which suggests that experimental diet exposure time significantly impacted results.
Accordingly, (BALF) neutrophils in treatment phase OVA animals fed high calcium diets
appeared reduced compared to control diet animals and though not significant it was a
trend not observed in prevention phase subjects. Also, in prevention phase all OVA
treated animals gained significantly less weight than their PBS counterparts (p<0.01) but
this trend was not significant in treatment phase animals with the exception of leucine
diet mice (p<0.05).
Our previous studies were conducted in aP2-agouti transgenic mice that are
genetically predisposed to develop obesity but were not an appropriate model for asthma
(21). The current study was conducted in BALB/c mice; although this is an established
asthma model, BALB/c mice are lean, making it difficult to use in the study of dietary
modulation of airway function in obesity. By introducing high fat diets to BALB/c mice
we anticipated the generation of excess adiposity to produce an asthma model
incorporating characteristics of obesity. The combination of a mixed disease model,
sample size/power, and duration of the study may have hindered hypothesized results.
Still, high calcium and leucine-supplemented diets were able to significantly reduce the
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amount of eosinophils present in BALF of prevention phase OVA animals compared to
control diet mice. This decrease may have contributed to the lower pathological scores of
lung inflammation (iBALT) and airway remodeling (HypEpi) found in this group
compared to control diet animals although these trends were not significant. Results from
this study give only a modest indication of the potential of calcium and leucine in
attenuating obesity associated airway inflammation further research in this area is still
warranted.
5.6 Strengths, Weaknesses, and Limitations
The strength of this study is the generation a murine asthma model with lower
airway inflammation. Additionally, the BALB/c mouse strain is the ideal model for
translational asthma studies. However, the model is also a limitation as a lean mice strain
it is difficult to use in dietary modulation of airway function of obesity studies. For this
reason the BALB/c mouse model is both a strength (asthma) and a limitation (obesity) of
this study. The duration of the study and sample size is also a weakness of the study
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Part Six
Summary and Conclusions

114

Leucine and calcitriol appear to have opposing effects on adipocyte proinflammatory cytokine secretion. Experiments conducted in vitro suggest that leucine
provided an anti-inflammatory effect by decreasing leukocyte activation markers
(CD11b), decreasing adhesion molecule expression (ICAM-1), and subsequently
decreasing leukocyte adhesion to smooth muscle cells and endothelial cells. Extension of
these findings to an established murine model of asthma did result in a significant
decrease in eosinophils present in the bronchoalveolar lavage fluid (BALF) of BALB/c
mice fed a high calcium and leucine supplemented high fat diet compared to control diet
animals. Overall, however the animal study showed only modest effects of calcium and
leucine supplementation. The BALB/c mice strain (although ideal for asthma studies) is
lean, making high-fat diet induced obesity difficult and perhaps compromising the
desired model for this study. The prominent eosinophilic rich inflammation assessed by
collected BALF fluid as opposed neutrophilic inflammation suggests the obesity
associated asthmatic phenotype was not achieved in the BALB/c model. Nonetheless,
calcium and leucine supplementation did decrease eosinophil infiltration likely a result
decreased of leukocyte CD11b and lung endothelial cell ICAM-1 expression observed in
the in vitro studies.
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